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Abstract 
Assessing the Transport of Receptor-Mediated Drug Delivery Devices Across Biological 
Barriers 
Erik C. Brewer 
Advisor: Anthony M. Lowman, Ph.D. 
 
 
 
Administering therapeutics through the oral route or to the central nervous 
system presents significant challenges for large-molecule drugs, primarily due to the 
diffusive barriers and efflux mechanisms present in the cellular lining of the 
gastrointestinal (GI) tract and blood brain barrier (BBB). Receptor-mediated endocytosis 
(RME) has been extensively studied as a method for augmenting the transport of 
therapeutic devices across these barriers. These devices range from simple ligand-
therapeutic conjugates to complex ligand-nanoparticle systems. Customarily, 
characterizing the uptake of these carriers relies on their comparisons to the native 
therapeutic, which provides no understanding of ligand or cellular performance. 
Therefore, the focus of this research is to investigate the transport potential of the RME 
pathway itself, so that ligands can act as suitable benchmarks for success. 
To better understand the pharmacokinetics of the RME pathway, a model for 
barrier transport was designed based on the endocytosis cycle of transferrin, a ligand 
often used in RME drug-delivery research. This model established the correlation 
between apical receptor concentration and maximum transport capability. Experimental 
studies confirmed this relationship, demonstrating an upper transport limit independent 
of the applied dose. This contrasts with the dose-proportional pathways native 
xiii 
therapeutics rely on for transport. Thus, the direct comparison of these two transport 
mechanisms can produce misleading results that change with arbitrarily chosen doses. 
Furthermore, transport potential was hindered by repeated use of the RME-cycle. 
Commonly, nanoparticles are incorporated to amplify the payload capacity of 
RME-devices despite the burden they pose to the cell. The response of size and the size 
distribution of nanoparticle-ligand formulations on the cell were tested and contrasted 
to their increasing payloads. These results demonstrate that size has a major influence 
on nanoparticle transport, and future studies should base the success of this technology 
not on the performance of the therapeutic itself, but on the capabilities of the cell. Using 
receptor-binding studies, we were able to demonstrate how these capabilities can be 
predicted and potentially adopted for high-throughput screening methods. 
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Chapter 1: Introduction 
The cell linings of the gastrointestinal (GI) tract and the blood brain barrier (BBB) 
present significant obstacles for drug transport. The single-layer of cells that make up 
these barriers are joined by tight junctions, forming a continuous wall that limits the 
diffusion of all solutes, including therapeutics, to only lipophilic, low molecular-weight 
compounds, resulting in poor uptake of many drugs[1]. Peptide and protein 
therapeutics in particular are typically more difficult than other drugs to administer due 
to their low membrane permeability in the gastrointestinal tract, thereby eliminating the 
possibility of effective oral uptake and requiring parenteral routes of administration[2, 
3]. However, these routes are unpleasant and typically suffer from poor patient 
compliance, a problem exacerbated by the chronic nature of many of the diseases they 
are used to treat[4]. Thus, the oral route remains the preferred route of administration. 
Therapeutics intended for the central nervous system (CNS) to treat diseases 
such as cancers, HIV-dementia, strokes, ischemia, Alzheimer's and Parkinson's diseases 
suffer similar disadvantages due to the physiological similarities between the GI tract 
and BBB[5]. In these cases, even when intravenous administration is acquiesced, the 
endothelial lining of the barrier prevents their passage to the intended site of action. 
Other administrative routes to the brain, such as intracerebroventricular fusion or 
intracerebral implants, are highly invasive and require surgical access[6]. Less invasive 
options include disruption of the blood-brain barrier using compounds such as 
mannitol, which increase the permeability of therapeutics[7], though it has been shown 
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that this disruption can lead to chronic neuropathalogical changes[8]. Because of this, 
the largest challenge in the development of these drugs is not to find ones that treat the 
diseases of the CNS, but to design them to successfully cross the BBB[9]. 
Receptor-mediated endocytosis (RME) pathways offer an attractive and alternate 
route across these biological barriers, as their natural function is to transport larger, 
hydrophilic molecules across the cell wall using energy-driven mechanisms[10, 11]. 
Previously, ligand-receptor interactions have received considerable attention in drug 
delivery due to a number of beneficial traits they possess: therapeutics utilizing this 
interaction circumvent P-glycoprotein (P-gp) efflux transporters, the key mechanism 
responsible for multi-drug resistance; their high specificity allows for site-specific 
targeting; the ligands illicit low immunological responses; and receptor-mediated 
endocytosis (RME) permits intra- and transcellular passage of large molecules which 
would normally be prevented from permeating the cell wall[12-14]. Drug-delivery 
devices tethered to ligands have successfully taken advantages of these traits in a variety 
of applications: nanoparticles coated with cancer-specific ligands have been used to 
image early and developed tumors and detect peripheral metastases[15-17]; therapeutics 
have been directed to target cell-specific receptors to achieve localized delivery[18-20]; 
chemotherapeutic and gene transfect ion agents are made more effective when delivered 
within the intracellular endosomal pathway[20-25]. 
To achieve transcytosis, therapeutics or more complex therapeutic-encapsulating 
nanodevices are tethered to appropriate ligands, which attach to receptors on the cell 
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monolayer surface and carry the drug cargo through the endosomal pathway to the 
opposite side of the cell, where they are released into circulation. Unlike other ligand-
receptor drug delivery methods, the therapeutic is not intended to act on the "targeted" 
monolayer; the receptor pathway is only utilized to increase uptake of the drugs, and is 
not involved in their therapeutic action. For this reason, these RME-therapeutics are 
often referred to as "Trojan horses". 
Characterizing the uptake and transport behavior of these devices is a necessary 
process in the pharmaceutical industry, and ideally performed early in the drug 
candidate selection[26]. However, animal-based in vivo studies, a prerequisite for 
advancement to clinical trials, are time-consuming and are not suited for high-
throughput screening methods, and thus are performed at relatively late stages of the 
drug development process. It is preferred to instead rely on cell-based in vitro and 
physiologically based pharmacokinetic (PBPK) modeling to assess potential drug 
candidates before moving on to more complex studies. These methods have proven to 
be effective at predicting the absorption, distribution, metabolism, and clearance of 
therapeutics in the past[27]. 
The focus of this research is to investigate the impact of ligand-receptor kinetics 
on the transport of RME-based therapeutics and to determine a suitable benchmark for 
evaluating their success. An attempt is made to adapt PBPK models from literature for 
monolayer cell geometries in order to predict and analyze the transport kinetics of a 
representative ligand, transferrin. The transcytosis uptake of transferrin is then in 
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examined in drug permeability studies using common assessment techniques and 
compared to the results of model simulations. Furthermore, the potential for 
nanoparticle devices to both amplify drug transport and hinder the RME kinetics is 
investigated. 
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Chapter 2: Background 
2.1 Physiology of Biological Barriers 
2.1.1 Gastrointestinal Tract 
The gastrointestinal (GI) tract is a major component of the human digestive 
system and consists of the esophagus, stomach, the small intestine (comprised of the 
duodenum, jejunum, and ileum), the large intestine (comprised of the caecum, colon, 
and rectum), and the anus. The principal purpose of the GI tract is to break down food, 
absorb nutrients, and excrete waste from the human body[28]. 
The physical breakdown of food begins in the mouth, where food mixed with 
saliva is chewed and reduced in size. Digestion, which is the chemical breakdown of 
food, begins here as well, as enzymes secreted by glandular cells in the mouth start to 
act. Digestion continues in the stomach, where the major enzyme pepsin starts to breaks 
down large proteins into smaller peptides. The acidic nature of the stomach (pH 1.5-4) 
only indirectly aids in digestion by denaturing proteins and activating the inactive 
enzyme pepsinogen into pepsin[29]. Most of the digestion and absorption takes place in 
the small intestine. Here, carbohydrates are broken down by hydrolysis first by the 
enzyme α-amylase and then further by more specific enzymes, depending on the 
carbohydrate; Proteins are broken down by either endopeptidases (the most notable 
being trypsin) and exopeptidases; Lipids are hydrolyzed primarily by the enzyme 
lipase. The broken down components are then absorbed by the lining of the intestinal 
walls[30]. 
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The lining of the GI tract is composed of a single layer of epithelial cells 
comprising a mixture of columnar enterocytes, goblet, paneth, and endocrine cell-
types[31]. Goblet cells secrete mucin, which combines with water to form the unstirred 
mucus layer that lines the intestines, aiding in material mobility and protecting the 
stomach from acid (see figure 2-1). Paneth cells provide host defenses against microbial 
agents to the epithelial cells, while endocrine cells secrete hormones that control 
satiation, motility, and other functions of the intestines.   
Enterocytes, also called absorptive cells, are responsible for absorbing and 
transporting the digested nutrient products from the lumen into and across the cell, 
where they ultimately end up in circulation. To facilitate the large amount of nutrients 
being processed, these cells posses densely-packed microvilli, which are small, fold-like 
structures on the apical (lumen side) surface, that dramatically increase the available 
surface are of the cells, around 250m2 in humans[32]. 
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Figure 2-1: The epithelial lining [30] 
 
 
 
2.1.2 Blood Brain Barrier Anatomy 
Unlike the GI tract, the blood-brain barrier (BBB) does not refer to one or a series 
of organs, but rather is a description of the cellular structures that make up the 
capillaries separating circulating blood and extracellular fluid of the brain the central 
nervous system. The phenotype of these capillaries are distinctly different from 
capillaries in other areas of the body in that they heavily restrict the flow of large 
macromolecules, while also controlling and aiding in the transport of essential metabolic 
products. These barrier and transport properties, and similar properties found in the GI 
tract, are discussed in upcoming sections. This section will be dedicated to the 
physiology of the capillaries that make up the BBB. 
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At the core of the BBB is a continuous sheath of endothelial cells that line the 
capillaries (see figure 2-2). Most capillaries are made up a single endothelial cell forming 
the circumference of the vessel, while larger cerebral blood vessels are made up of 
several cells joined together[33]. Below these cells (the outer circumference) sits a 
basement membrane made up collagen, fibronectin, laminin, and proteoglycans. Sharing 
the basement membrane are contractile cells called paricytes. As the endothelial layer 
lacks smooth muscle, these cells provide structural support through both their 
morphology and secreted factors[34]. For instance, the density of paricytes has been 
shown to be directly correlated with the vascular ability to counter high blood 
pressure[35]. In addition, paricytes have shown to provide a supporting role in 
endothelial growth and angiogenesis[36]. 
While endothelial cells and paricytes are common to all capillary structures, the 
BBB features a unique glial-cell type knows as astrocytes, whose star shaped "feet" cover 
>99% of the basal lamina[37]. Astrocytes, which provide structural, metabolic, and 
signaling functions to the brain, have been shown to be vital to the development of the 
barrier functions of the endothelial cells, suggesting a complexity greater than those 
barriers found in the epithelia of the GI tract. For example, while epithelial cells grown 
in vitro develop their barrier functions by themselves, BBB-derived cells cannot do so 
without being co-cultured with astrocytes[38]. Furthermore, in vitro co-cultures of 
chorioallantoic membranes, taken from cells in chick eggs, and astrocytes taken from 
neonatal rat brains were found to induce BBB-like permeabilities, much lower than those 
11 
 
observed in cultured chorioallantoic membranes alone[39]. This indicates the 
importance of the underlying cellular structure of the endothelial layer to the 
development of the regulatory properties of the BBB.  
 
 
Figure 2-2: Blood-brain barrier cellular anatomy[40] 
 
 
 
2.1.3 Components of Monolayer Barriers 
One of the two primary purposes of the biological barriers found the GI tract and 
BBB is to serve as a protective mechanism from external environments. The lumen of the 
GI tract is host to a colony of bacteria that, under normal conditions, provide functions 
in metabolic and nutritional homeostatis; in cases where the protective barrier of the 
intestinal lining is compromised, these micro-organisms and their toxins pose serious 
health risks[41]. The BBB protects the brain from variations in plasma compositions and 
toxins: amino acids, hormones, and potassium levels all fluctuate frequently, in 
particular after meals, and the BBB help to prevent these fluctuations from crossing over 
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and disrupting brain activity[42]. In addition, the BBB effectively protects the brain from 
bacterial infections[43]. 
The epithelial lining of the GI tract and BBB share many common components 
that make up these protective features. Each one of them poses a unique restriction to 
therapeutics trying to cross these barriers. They are: 
(1) Mucus barrier [GI tract only] - The intestinal lumen is covered with a mucus 
layer consisting mostly of glycoproteins and water with trace amounts of lipids, nucleic 
acids, and other proteins (see figure 2-1)[44]. It serves to protect the gastric epithelial 
surface from the digestive enzyme pepsin found in the lumen[45]. Though this layer has 
been found to be of limited consequence to the transport of small, absorbable solutes[46], 
it acts as a diffusive barrier to larger sized proteins and other therapeutics[47, 48]. 
(2) Paracellular barrier - The intercellular junction complexes of the cellular 
lining is composed of three parts: the apically located tight junctions, the underlying 
adherens junctions, and the basolaterally located desmosomes[49]. The latter two are 
cadherin-containing anchoring compounds that link keratin (desmosomes) and actin 
(adherens) filaments of the cytoskeletons of adjacent cells, helping mediate cell-to-cell 
adhesion and to resist sheer stress[50]. These anchoring compounds have also been 
shown to be crucial the development and formation of tight junctions[51]. 
The tight junctions have fenestrae, or pores, that have an effective radius of 4-9Å, 
effectively eliminating the intercellular space and allowing only the passage of ions and 
small nutrients[52, 53]. Serving as the backbone to these monolayer barriers, tight 
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junctions define two of their major defining principles: the polarization of the cells into 
separate apical and basal sides, called the 'fence function', and the restriction of the 
paracellular pathway, routing all transport through the phospholipid bilayer and its 
transcellular mechanisms, called the 'gate function'[54, 55]. 
(3) Transcellular - For molecules to achieve transcytosis across the cell layer, they 
must pass through using either passive diffusion, carrier-mediated transport, or vesicle-
mediated transport. The phospholipid bilayer of these cells are hydrophobic, and are 
therefore permeable to small, lipophilic molecules by means of diffusion; for passive 
transcellular transport to occur, molecules should have a molecular weight less than 
450Da and a total polar surface area less than 90Å[56]. Larger and more hydrophilic 
molecules, including many nutrients, are excluding from this pathway and rely on 
alternative transport means, discussed in section 2.3. Hydrophilic drugs, including all 
protein therapeutics, are weakly permeable across the lipid membrane. 
(4) Enzymatic - Solutes and therapeutics attempting to cross the BBB encounter a 
large variety of degrading enzymes designed to protect the central nervous system. 
Examples include acetylcholinesterase, alkaline phosphatase, gamma-glutamyl 
transpeptidase, monamine oxidases, and catechol O-methyl transferase[57, 58]. In the 
small intestine, epithelial cells contain and secrete a plethora of therapeutic-degrading 
enzymes into the intestinal lumen, including trypsin and α-chymotrypsin[59]. 
(5) Active - the endothelium possess of the BBB and epithelial cells of the 
intestinal lining feature a number of efflux transporters, known as ATP-binding cassette 
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(ABC) transporters, that facilitate detoxification by removing xenobiotics using energy-
driven mechanisms[60-62]. While the preceding barrier mechanisms hinder the 
successful penetration of drugs, efflux transporters hinder the accumulations of drugs 
that have made it across the monolayers by actively pumping them towards the outer 
(apical) side. P-glycoprotein (P-gp), an often-studied ABC transporter, has such a broad 
specificity that it has been shown to be involved in the efflux of a number of structurally 
unrelated drugs[63, 64]. Therapeutics found to be substrates of P-gp efflux mechanisms 
have been found to suffer from poor bioavailability, even when exhibiting high 
transmembrane permeabilities, due to P-gp efflux[65]. Cell and animal models 
genetically modified to lack the P-gp protein have shown significant increase in CNS 
brain accumulation[66, 67]. 
2.2 Transcytosis Across Monolayers 
The previous section outlined the restrictive components of the two monolayers 
barriers in the body that constitute its "protective function". Though extracellular lipids 
essential for cell function easily traverse the cell membrane through passive diffusion, 
other essential nutrients and molecules require more specialized transport mechanisms 
to be carried across the cell membrane due to their restricted permeability. While many 
of these pathways exist in other cell types for intracellular transport, their function in the 
BBB carries the dual-roles of intra- and transcellular pathways. This introduces the 
second principal purpose of monolayer barriers, which is that of a "carrier function". 
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Figure 2-3: Transcytosis pathways across monolayers[68] 
 
 
 
2.2.1. Carrier-Mediated Transport 
Carrier-mediated transport, also known as active membrane transport, involves 
the passage of solute molecules across the cell membrane through the assistance of 
proteins embedded in the lipid bilayer. These carrier proteins have specific affinities to 
one or more substrates, and, when bound together, undergo reversible conformational 
changes that expose the substrate first to the external side of the membrane, and then to 
the internal side, before releasing it to the inside of the cell[69]. Active membrane 
transport occurs when carrier proteins require energy to carry substrates against 
concentration gradients. Energy is derived either through the direct hydrolysis of 
adenosine triphosphate (ATP) (termed primary active transport) or by coupling with the 
downhill transport of a solute with a greater electrochemical gradient (termed secondary 
active transport, since these downhill solutes require ATP to carried back out)[70]. 
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Though these proteins exist in all cell types, the monolayer cells of the GI tract 
and BBB are tasked with absorbing and supplying nutrients to the body and central 
nervous system, respectively. Thus, they have carrier-mediated transport proteins 
distributed non-uniformly across the two sides of the cell, creating a basolaterally-
directed nutrient flow, facilitating nutrient absorption[71]. Glucose, for example, is 
internalized within monolayer cells on the apical side against concentration gradients 
using the coupled-carrier protein SLGT1, powered with Na+-ions, where it then released 
to the basolateral extracellular fluid via the GLUT1 carrier protein down its 
concentration gradient (termed facilitated diffusion)[72]. P-glycoprotein (P-gp), the efflux 
carrier previously discussed in section 2.2.3, is another example of an ATP-driven carrier 
protein. In this case, the P-gp is predominately located on the apical side of the GI 
tract[73] and BBB[64], facilitating transport in the opposite direction from nutrients. 
Carrier-mediated transport systems have been shown to be partially responsible 
for the uptake of certain small-molecule drugs. Antibiotics, such as cefadroxil, ceftibutin, 
and captopril, are transported by H+-powered oligopeptide transporters in the intestinal 
cell wall and in vitro cell models[74, 75]. The epileptic drug gabapentin is partially, 
though not efficiently, absorbed via amino acid transporters, as are other amino acid 
analogues like α-methyl dopa, L-dopa, and baclofen[76-79]. Strategies have emerged to 
improve the transport low-permeating drugs by taking advantage of these carriers: the 
bioavailability of α-methyldopa was proven to improve through the covalent 
attachment of di- and tri-peptide compounds, creating a prodrug which took advantage 
17 
 
of oligopeptide transporters[80]; Such strategies have proven to work with 
carbohydrate[81] and  bile-acid transporters[82] as well. No successful cases of these 
strategies were found with larger molecule peptides and therapeutics, likely due to their 
steric hindrance on the carrier proteins conformational changes. 
2.2.2 Endocytosis Transport 
Endocytosis, or vesicle-mediated transport, is the cellular uptake of 
macromolecules and solutes in membrane bound vesicles, called endosomes, formed by 
pinching off sections of the phospholipid bilayer[71]. These mechanisms help serve 
many important cellular functions, such as the uptake of extracellular nutrients not 
served via carrier-mediated transport, the regulation of cell surface receptor expression, 
maintenance of the cell membrane, antigen presentation, cell adhesion and migration, 
and cell signaling. These ATP-driven processes can be placed into three classes: 
Phagocytosis, receptor-mediated endocytosis (RME), and pinocytosis. 
The third type of vesicle-mediated transport, pinocytosis, or bulk- or fluid-phase 
endocytosis, is a process where the cell engulfs portions of the extracellular fluid, along 
with the dissolved solutes present, and brings them into the cell. This endosome then 
fuses with lysosome and the contents are degraded by intracellular enzymes. In contrast 
to phagocytosis and receptor-mediated endocytosis, this process forms smaller vesicles 
and is non-specific. Because there are no interactions with the cell membrane, the 
concentration of the endosomal fluid are the same as that of the extracellular fluid. In 
addition, the kinetics of pinocytosis are considerably slower than phagocytosis and 
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receptor-mediated processes[83]. Therefore, of the three endosomal processes, 
pinocytosis receives the least amount of attention in drug delivery research, and will not 
be discussed further here. 
2.2.2.1 Phagocytosis 
Phagocytosis differs from other types of endocytosis processes in that is designed 
to take up large particles, such as bacteria, foreign bodies, and other cells, rather than 
solutes[84]. The size of these particles ranges from 0.5µm to up to 10µm[85]. Unlike 
pinocytosis and receptor-mediated endocytosis, phagocytosis only occurs in specialized 
cells such as macrophages, monocytes, and neutrophills[86]. These cells use 
phagocytosis to ingest microorganisms and initiate inflammatory or immune responses, 
or to dispose of dead neighboring cells[69]. Other organisms like amoebae use 
phagocytosis for feeding. 
Phagocytotic cells recognize their targets through compounds known as opsonins 
which circulate and collect on the surface of macromolecules. Examples of opsonins 
include antibodies, which attach to foreign antigens, and complement proteins, which 
attach to dead cells[87]. Once recognized, the opsonins attach to specific receptors at the 
plasma membrane of the cells. The membrane protein actin facilitates the formation of 
the vesicle, which engulfs the macromolecules and absorbs it into the cell, forming a 
phagosome[88]. These bodies fuse with lysosomes to form phagolysosomes, enzymes 
continue to break down the substrates.  
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Due to their ability to transport large particles, microfold cells (M-cells) in the 
Peyer's patches of the GI tracts have been targeted for oral drug delivery strategies. 
Further aiding these strategies is the reduced hydrolase and enzyme activity of these 
cells compared to normal epithelial cells, which is particularly important for protein 
therapeutics[89]. Endothelial cells in the brain have also shown to be successfully 
transcytose drug-delivery vehicles via phagocytosis[90].  
However, this mode of transport is also targeted by disease causing pathogens, 
which escape lysosomal degradation by utilizing certain survival strategies, such as 
disrupting the phagosome membrane with secreted toxins, inhibition of the 
phagosome/lysosome fusion process, and enhanced DNA repair[69]. Bacteria have been 
shown to translocate across epithelial enterocytes via phagocytosis, and is thought to be 
a precursor to systemic sepsis[91]. Yeasts from the genus Cryptococcus have been shown 
to cross into the central nervous system through phagocytosis through the BBB after 
inhalation, resulting in potentially fatal lung diseases[92].  
2.2.2.2 Receptor-Mediated Transport 
Receptor-mediated endocytosis (RME) involves the uptake of specific 
extracellular macromolecules, called ligands, following their binding to complimentary 
receptors on the cell surface[93]. This mechanism allows for the efficient uptake of 
ligands that may be present at low concentrations in the extracellular fluid. These 
receptors tend to cluster in specialized domains known as coated pits, which contain 
proteins that aid in the formation of the endosomal vesicle (RME vesicles are also known 
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as "coated vesicles" for this reason)[94]. Two of the best-understood vesicle formation 
mechanisms include the membrane proteins clathrin and caveolae. Previously, it had 
been thought RME process could be subdivided between two groups named after these 
proteins (clathrin-mediated and caveolae-mediated endocytosis), though new studies support 
that further mechanisms independent of these membrane proteins exist[95, 96]. 
Cellular receptors serve a variety of functions which can be categorized as 
serving two purpose: housekeeping functions and signaling functions[85]. 
Housekeeping receptors are tasked with the uptake of materials to be used by the cell, 
such as iron by the transferrin receptor (discussed below) and cholesterol by the low-
density lipoprotein (LDL) receptor. Signaling receptors, when bound with their ligand, 
carry messages that instruct the cell to perform specific cellular functions. Examples of 
signaling receptors include many hormones, such as insulin, and growth factors, like 
epidermal growth factor (EGF)[97].  
Following internalization of the ligand-receptor complex, vesicles are routed 
along a generalized endosomal pathway described as follows: vesicles first develop into 
early or sorting endosomes, which begins to acidify, facilitating the release of the ligand 
from its receptor[98]. Housekeeping receptors are then recycled back to the plasma 
membrane here, while ligands and other receptor types progress to the late endosome 
stages[99]. Here, pH levels drop further, activating degradation enzymes that begin to 
hydrolyze the vesicle cargo. Late endosomes progress into lysosomes, which complete the 
breakdown of degradation of the internalized components. The destruction of the 
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receptor serves as a feedback mechanism that prevents overstimulation of the cell[100, 
101].  
More complex endosomal sorting patterns are exhibited by polarized cells of the 
GI tract and BBB, where early endosomes destined for either apical or basolateral side 
are directed by different mechanisms. The exact nature of these sorting cycles, and how 
they differ from non-polarized cells remains to be determined[102]. This is further 
complicated by the variety of pathways observed in literature that, though similar to 
each other, are unique to each ligand/receptor system.  
Transferrin 
Humans contain approximately 4-5g of iron in the body, which is required for a 
variety of critical functions, notably oxygen transport, in addition to serving as a 
cofactor for enzymes that detoxify chemical agents, reduce hydrogen peroxide, and 
synthesize chetachloramine, collagen, and precursors of dopamine and adrenaline[103-
105]. At physiological conditions, iron exists in its ferric state (Fe3+), which is toxic and 
considerably insoluble. To aid its circulation and solubility, iron is transported by a 
series of carriers, one of which is transferrin. Transferrin is a 80kDa protein that has a 
high affinity to iron and contains two ferric binding sites[106]. The uptake of iron and 
transferrin into cells is facilitated by the transferrin receptor, a transmembrane 
glycoprotein composed of two identical 95kDa subunits linked together by a disulfide 
bridge; each of these subunits is capable of binding two ligands[107]. Diferric transferrin 
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has a high affinity towards its receptor at physiological pH (Ka ~109 M-1)[108], while 
monoferric and apo-transferrin (iron-less) have 4.4-fold and 24-fold lower affinity[109].  
Once bound, the transferrin/receptor complex is internalized via clathrin-
mediated endocytosis, and the vesicle develops to the early endosome stage[110]. Here, 
proton pumps increase the acidity levels of the vesicle until the pH drops to around 5.0, 
causing transferrin to shed its iron molecules, which are then brought into the cell. 
Under these conditions, the affinity of apotransferrin is much higher, and the ligand 
remains attached to the receptor[111]. This is atypical for most ligand/receptor 
combinations, as even recycling housekeeping receptors, like the LDL receptor, shed 
their ligand during the endocytosis process. At this point, transferrin ligand/receptor 
endosomes recycle back to the plasma membrane, foregoing the late endosome and 
lysosome degradation states[97], though at high extracellular ligand concentrations, a 
small percentage of these vesicles are routed to late endosomes for degradation, likely 
for the purpose of down-regulating the receptor [112, 113]. At the plasma surface, 
apotransferrin is released from the receptor due to the restoration of physiological pH 
conditions, where it returns to circulation to pick up more ferric ions and repeat the 
process. 
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Figure 2-4: The Transferrin Cycle[114] 
 
 
 
2.3 Receptor Mediated Drug-Delivery Strategies 
Due to the high affinity and specificity of ligand-receptor complexes, there is 
considerable interest in drug-delivery research to take advantage of ligand-receptor 
complexes; Not only do they aid in cellular recognition, but the trafficking pathways 
and subcellular sorting allow for more direct routes to the sites of therapeutic 
action[115]. To utilize these interactions, therapeutics can be linked with the desired 
ligand through a number of mechanisms: Fusion proteins can be co-synthesized to 
contain both ligand and therapeutic functional groups[116, 117]; synthesized or natural 
therapeutics can be covalently conjugated through a number of cross-linking 
mechanisms[118]; and the ligand and therapeutic can be linked together with non-
covalent, high affinity biological affinity partners, such as the biotin-avidin pair[119, 
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120]. Directly linking in these manners allows for a limited number of drug molecules to 
be attached, depending on the size of the ligand and drug. In doing so, care must be 
taken that the affinity of the ligand and efficacy of the drug are not hindered due to the 
attachment of each other[121]. Alternatively, particle drug delivery vehicles can be used 
which encapsulate the therapeutic. These vehicles are then linked to the ligand using 
similar methods as those listed above. This frees the therapeutic from the hindrances of 
direct conjugation and takes advantage of the numerous benefits of particle drug 
carriers, which are discussed further in section 2.4.  
The use of ligand-receptor systems in targeted drug delivery can be classified in 
three applications: achieving localized or site-specific therapeutic delivery, targeting the 
endosomal compartments for intracellular delivery, and utilizing endosome routes for 
transcellular transport. These applications are discussed in the following sections.    
2.3.1 Site-specific Drug Delivery 
Early adoptions of ligands into therapeutic designs focused on the strong affinity 
between ligands and their receptor to achieve localized delivery. Cuna et al. developed 
chitosan nanoparticles that associated with mannose recpeotors in the GI tract, which 
provided stability of the nanoparticle in the intestinal lumen and could facilitate the 
localized release of encapsulated therapeutics[122]. This also increased residence time in 
the GI tract, allowing for longer drug-release mechanisms. Ligands that have affinity to 
receptors found only on specific cells also allows for site-specific targeting as well. For 
instance, microparticles have been developed with surface bound ligands that target 
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inflammatory sites using leukocyte-like adhesion mechanisms[123]. In another study, 
macrophage cells in the GI tract were targeted by microparticles using M-cell specific 
ligands to successfully induce presentation to the immune system[124]. 
This technology has been used prominently in cancer research, as cancerous cells 
tend to over-express receptors, particularly ones that are involved in nutritional and 
metabolic pathways due to the increased growth rates of cancer cells. Attaching 
targeting ligands to the therapeutic or nanoparticle carrier can take advantage of this 
over-expression, as the drug delivery devices then accumulate at the targeted site in 
higher concentrations than at healthy cells[125, 126]. For example, folate receptors are 
known to be vastly over-expressed in several human tumors [127-129]. Attaching folate 
to the outer shell of particles can create a targeted drug delivery carrier. Folate 
conjugation has shown success at creating targeted anti-cancer agents that can avoid 
non-specific attacks on normal tissue and increase cellular uptake within target cells 
[125, 126, 130-132]. Transferrin is also considered a promising target, as transferrin 
receptor levels in cancerous cells can be up to 100-fold higher than the amount on 
normal cells[133, 134]. Coupled with natural tendency of tumors to accumulate nano- 
and microparticles due to their leaky vasculature, an effects known as the enhanced 
permeability and retention (EPF) effect, targeted particles can increase the interaction 
time between particles and the tumor cell and increase the likelihood of the particles 
accumulating at the desired site[130].  
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PEG is commonly associated with the surfaces of micelle-like particles and 
liposomes to increase particle circulation. By coupling ligands to polyethylene glycol 
(PEG), a targeted particle can be created where the ligand is expressed on the particle 
surface. By combining the benefits of prolonged particle circulation with the benefits of 
delaying drug release, more efficient drug delivery devices can be created[135-137]. Yoo 
et al. developed folate-conjugated PEG-co-poly(lactic-co-glycolic acid) (PEG-PLGA) 
micelles loaded with the anti-cancer drug doxorubicin that expressed folate on the 
micelle surface[130]. Studies indicated increased cytotoxicity and decreased tumor 
growth for folate conjugated micelles as opposed to non-targeted micelles and free DOX 
[130]. 
2.3.2 Intracellular Drug Delivery 
As ligand-receptor systems became more commonly used with cancer 
therapeutics, RME-drug delivery devices became more sophisticated as researchers 
focused on utilizing the endosomal pathway to deliver drugs within the cell. This was in 
part to combat multiple drug resistance (MDR), a condition that develops as plasma-
membrane P-gp efflux carriers learn to recognize xenobiotics[138], and actively transport 
them out of the cell. RME-drug devices can circumvent MDR by bypassing the plasma 
membrane and traveling along the endosomal route[139, 140]. For drugs that have 
difficulty attaining cytosolic concentrations because of the P-gp efflux system, 
intracellular nanoparticles can act as drug depots that constantly release their 
payload[141]. 
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In order to selectively trigger the release of therapeutics into the endosomal 
compartment and not prior, RME-drug delivery systems often tailored to take 
advantage of the low-pH environments of the endosome. This first became a desirable 
property by the observation that certain viruses take advantage of the endosomal 
acidification to infect cells[142]. For example, Bae et al. developed pH-responsive 
micelles that targeted the folate receptor, which is known to over-express on cancer 
cells[143-146]. The core of the micelles had doxorubicin, a chemotherapy drug, 
covalently linked using a pH-sensitive hydrazone bond that released the drug under 
acidic conditions. These micelles were shown to selectively release their payload within 
tumor cells due to this pH-effect[147-149]. Micelles without the folate ligand required 
doses twice that of targeted micelles to achieve the same effect, suggesting that both 
targeted and intracellular-release properties combined formed superior delivery 
devices[143, 146]. Liposomes with pH-sensitivity, often composed of 
phosphatidylethanolamine, and targeting ligands have been effectively used to increase 
residence time at the target cells, increase uptake, and increase intracellular delivery 
[131, 142, 150-152]. 
Another option to receive intracellular delivery of therapeutics is to specifically 
target receptor pathways that undergo clathrin-dependant RME, which leads to fusion 
with lysosomes a breakdown of the endosome, leading to the release of their contents. 
This is desirable for chemotherapy and enzyme replacement therapies[115] Likewise, 
ligands that are recycle back to the cell surface along with their receptor, like transferrin 
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and riboflavin, have limited utility for therapeutics that require intracellular 
accumulation[153, 154]. 
2.3.3 Transcellular Drug Delivery 
Transcellular delivery is a unique application in RME scenarios as the targeted 
areas (i.e. the GI tract or BBB) are not the ultimate site for therapeutic action: drugs are 
intended to cross these biological barriers and then proceed onwards to act on other 
areas of the body. This application has its origin in the use of non-targeted, larger 
microparticles, which are naturally selected by phagocytic cells in the epithelial and 
endothelial lining and taken up through phagocytosis. As this mechanism became better 
understood, researchers realized they could target specific receptor-mediated 
endocytosis pathways through ligand conjugation to potentially increase transport of 
drugs through the GI tract and BBB. This approach is thought to me more favorable than 
permeation enhancing methods that disrupt barrier tight junctions, thus 
indiscriminately allowing both therapeutics and pathogens or other foreign substances 
to diffuse through[155]. 
Since transcellular delivery is desired, housekeeping ligand-receptor systems 
that recycle their ligands and evade lysosomal degradation are utilized. Transferrin (Tf), 
for example, remains bound to its receptor complex and recycles back to the plasma 
membrane without being recycled, and has thus been extensively studied for its 
transcytosis drug-delivery potential. The Tf-receptor lends itself particularly to oral 
delivery as it is expressed in abundance on the epithelial cells of the GI tract[156-158]. 
29 
 
Furthermore, Tf is resistant to enzymatic digestion from both the trypsin and 
chymotrypsin enzymes found in the intestines[159]. Tf-insulin conjugates have shown to 
exhibit superior GI transport and efficacy compared to insulin alone in both in vitro and 
in vivo models[160-162]. Nanoparticle-Tf delivery vehicles have shown to further 
improve the efficacy of insulin compared to the conjugates and drug alone[163]. The Tf-
receptor is also highly expressed in the BBB, and has been utilized to enhance transport 
of the painkiller loperamide in nanoparticle formulations[164], neural enzyme 
inhibitors[165], chemotherapy drugs[166], peptides[167], and genes[168]. 
Beyond Tf, conjugation to vitamin-B12 (V-B12), a cobalt-carrying ligand necessary 
for the production of folate, has also demonstrated to improve transport of insulin, the 
growth hormone erythropietin (EPO) [169], luteinizing release hormone[170], α-
interferon, and granulocyte colony-stimulating factor (G-CSF)[171, 172]. During in vivo 
studies, however, the researchers noted the limited uptake capacity of V-B12 in the GI 
tract. Nanoparticle delivery vehicles, having a higher payload than therapeutic-V-B12 
conjugates, were shown to amplify the capacity of this pathway[173, 174]. In other 
studies, ligands that have demonstrated improved intestinal or BBB transport include 
various immunogoblins[175, 176], intracellular adhesion molecule-1 (ICAM-1)[177], and 
galactosylated lysine and histone[178, 179]. 
2.4 Nanoparticulate Drug Delivery Vehicles 
Nanoparticles generally refer to colloidal carriers that have diameters less than 
1µm, though the size threshold that separates nano- and larger microparticles is 
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arbitrary and often varies[180]. Over the past few decades, nanoparticles have been 
studied extensively for their use as drug-delivery vehicles, due to the number of 
advantages they provide: (1) their modifiable surface makes it possible to attach 
biologically active molecules, targeting sequences, fluorescent or other imaging and 
tagging devices, biocompatible coatings, and other accessories[181]; (2) they can protect 
the encapsulated drugs from the degrading enzymes found in both the GI tract and 
endothelia layer of the BBB[182]; (3) nanoparticles can increase the stability and 
dissolution of the encapsulated therapeutic; (4) nanoparticles can be tailored to provide 
customized release kinetics, such as long-term, bi-phasic (i.e. burst, followed by slow 
extended release), and stimuli-triggered release patterns[183, 184]. Nanoparticles appeal 
to researchers across many disciplines due to the ability to instill multiple properties that 
might be impossible for a single device to possess 
Nanoparticles come in a wide variety of morphologies and are made of a variety 
of materials, including polymers (polymeric nanoparticles, micelles, and dendrimers), 
lipids (liposomes),  and organometallic compounds (nanotubes). Polymeric 
nanoparticles are typically made up of biocompatible and biodegradable materials, such 
as gelatins, chitosan, poly(lactic acid), poly(glycolic acid), poly(methylmethacrylate acid) 
and poly(butyl)cyanoacrylate. These polymers can be combined to produce randomized 
or block co-polymers, whose composition and molecular weight determines the extent 
of drug release[185]. Furthermore, the surfaces of nanoparticles can be customized with 
additional polymers to change their pharmacokinetic properties[Faraji-24-26]. For 
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instance, poly(ethylene glycol) is often covalently attached to the surface of 
nanoparticles to prevent their recognition of phagocytotic cells and subsequent 
elimination from circulation, increasing their residence time[186, 187]. 
Micelles consist of a hydrophobic core and a hydrophobic corona and are well 
suited to entrap and solubilize hydrophobic drugs within their core. Because some of the 
most commonly used cancer drugs are hydrophobic, micelles have gained widespread 
use for the delivery of cancer therapeutics[147, 188-194]. Liposomes typically involve a 
bimolecular phospholipid membrane that encloses an aqueous compartment. Because 
liposomes contain a phospholipid membrane they can entrap hydrophobic drugs, but 
they can also encapsulate various hydrophilic drugs such as peptides, proteins and 
nucleic acids within their aqueous compartment [195, 196]. Previous work has been 
done to increase liposome stability by increasing circulation time and by preventing 
drug leakage until the target is reached [197-199]. Micelles, like particles and liposomes, 
with pH-sensitivity have shown great promise as delivery vehicles for anticancer drugs, 
DNA, RNA, proteins and peptides [142-151, 200, 201]. 
Nanoparticles provide the benefit of being able to carry multiple drugs in the 
same vehicle. This, combined with surface-bound ligands, can be used to selectively 
deliver dual-drug payloads to targeted cells. Due to their different mechanisms of 
action, the drugs may provide additive or synergistic effects that can allow for lower 
doses, and reduce side effects [202, 203]. More importantly, this is thought to combat 
drug resistance, a major problem associate with cancer drug treatment [204]. Packaging 
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the drugs in a nanocarrier, as opposed to a simple mixture, allows for their simultaneous 
delivery on a cell-by-cell basis, which has been proven more effective [205-207]. 
Nanoparticles are of considerable interest for receptor-mediated transport 
application because of their ability to carry larger payloads. Ligands are only able to 
carry a limited number of drug molecules (typically no more than 3) before losing their 
affinity to the receptor due to steric hindrances and changers in their conformation[23]. 
Nanoparticles, on the other hand, amplify the uptake capacity of RME pathways by 
carrying a larger cargo than single ligand conjugates can[163], with individual 
nanoparticles capable of carrying thousands of drug molecules. The capacity of these 
particles is a function of their size, with larger ones capable of carrying more 
therapeutics than smaller particles[208]. 
2.4.1 Characterizing Nanoparticles size 
The instrumentation and methods used to determine nanoparticle sizes can 
divides into two categories. The first method requires direct measurement of particle 
dimensions, usually using a visualization technique. The most commonly technique for 
this method is scanning electron microscopy (SEM), where an electron beam is focused 
on dried particle samples coated with a thin layer of gold or platinum, and an image is 
formed from the detected scattered electrons[209]. Transmission electron microscopy 
(TEM), a similar technique that relies on the transmission rather than scattering of 
electrons, has also been used to image and measure nanoparticles[210, 211]. Atomic 
force microscopy, a technique that uses a cantilever capable of correlating minute 
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deflections caused by atomic forces to the surface topography of a sample, has also been 
used to measure particle dimensions[212]. The second category of particle size 
measurements are indirect methods that rely on the relationship between particle 
behavior and size. The most common of these methods is light scattering, also known as 
photon correlation spectroscopy, which relates the intensity of scattered light directed 
on particles in suspension to their size. Other methods include laser light 
diffraction[213], capillary electrophoresis[214], and size-exclusion chromatography[215].  
The two most commonly used methods found in literature for characterizing 
nanoparticle size are dynamic light scattering (DLS), a version of photon correlation 
spectroscopy, and SEM. Of the two, SEM provides the most direct picture of 
nanoparticle size, shape, and other physical attributes[216]. In addition, SEM is capable 
of distinguishing multi-modal size profiles (those with more than one dominant size). 
DLS is far superior in terms of convenience, as it is capable of produce rapid results with 
little preparation, and is well-suited for routine measurements[217]. In addition, DLS 
units require no calibration[218]. On the other hand, DLS relies on the assumption that 
samples are spherical, and is incapable of providing more descriptive data other than an 
assumed diameter. Furthermore, this method is not reliable for analyzing samples with 
mixed populations, particularly if they overlap[219].  
Each method has its own unique way of presenting data, and must thus be 
interpreted differently. Images from SEM are analyzed, usually with automated 
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software assistance, to count and size each particle to then produce a number-average 
particle diameter size, which is produced using the following equation[220]: 
Eq. 2-1: ௔ܰ௩௚ = ∑ ௡೔ௗ೔௡೔  
In addition, all size averages must be accompanied by a term describing the 
range or distribution of particle sizes in a given sample, often called the polydispersity; 
Either tem by itself is without context and provides little information[221]. In the case of 
SME, Navg values are accompanied by a standard deviation of the counted samples; this 
is not to be confused the error that describes the differences in means from analyzing 
multiple images, itself a common practice.  
DLS obtains its raw data from the intensity of scattered light, from which it can 
obtain an average diffusion coefficient for all particles, which is then related through the 
Stokes-Einstein equation to the average particle diameter, signified by Zavg to distinguish 
it from other averaging methods[222]. Accompanying this value is a polydispersity 
index, PdI, a dimensionless number from 0 to 1, with 0 signifying a completely 
monodisperse solution. The threshold between "monodisperse" and "polydisperse" is 
arbitrary, often defined as PdI<0.1[223, 224], though some sources are more 
stringent[225]. Unlike standard deviations from number-weighted averages, which are 
absolute indexes, PdI is a relative index that is proportional to the Zavg value. If one 
were to assume a particle sample has a single population that follows a Gaussian 
distribution, these two indexes could be compared as shown below[226]: 
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Eq. 2-2: ܲ݀ܫ = ఙమ௓ೌೡ೒మ 
Comparing Navg with Zavg values is not a straightforward task: The intensity of 
scattered light is proportional to the particle diameter to the sixth power, is thus 
weighted more heavily on larger particles. Still, it is possible to convert Zavg results from 
DLS to number-average values in order to compare results from SEM imaging, and has 
been previously done[227-229]. This requires highly accurate readings from samples free 
from contamination, due to the high sensitivity of DLS units to large particulate matter, 
such as dust, which can skew the readings (such contamination would be readily 
noticeable and discounted in imaging methods). Even so, such conversions required 
detailed knowledge of the particle shapes, size distribution, and accepting a number of 
assumptions[230]. 
2.4.2 Importance of Size 
Nanoparticles have long been investigated as drug delivery vehicles, and it is 
well known that their biodistribution is a factor of their material composition, surface 
properties, and particle size[Park 2011-4-6]. With the emergence of endocytosis 
pathways as promising routes for intra- and transcellular therapeutic delivery, these 
factors, it is generally agreed, albeit with less literature support, that these factors, 
particularly size, also impact cellular uptake, with smaller particles being more easily 
transported[des rieux-22]. This is in contrast to a particles payload contrast, which is 
proportional to the mass of the particle and increases with size[231]. The sections below 
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highlight known studies that support size-dependency effects of particle uptake in both 
non-targeted and receptor-targeted endocytosis pathways.  
Non-targeted 
In the early history of nanoparticle drug delivery vehicles, phagocytosis was a 
mechanisms often utilized as it requires no external targeting antigens. Before 
nanotechnology became prevalent in research laboratories, larger microparticles were 
more common, and these devices were naturally directed to the endosomes of 
phagocytic cells, which form several micrometer-sized vesicular compartments, making 
them highly suitable for cell internalization of drug delivery vehicles[25]. Since no other 
endosome vesicles are this large, particles with diameters greater than 1µm are generally 
assumed to undergo phagocytosis[232].  
Despite the large vesicle sizes, smaller nanoparticles have shown to impact the 
rate of uptake: Lin et al. found that endocytosis of drug-delivery micelles directed 
towards phagocytosis routes was not hindered when their diameter was 70nm, 
however, when size was increased to 120nm, a significant drop-off in the internalization 
rate was observed[233]. Desai et al found that 100nm particles had a 2.5 greater uptake 
than 1µm particles, and a 6-fold greater uptake than 10µm in in vitro Caco-2 cell 
models[234]. In a follow up study using a rat in situ intestinal loop model, nanoparticles 
were shown to be successfully taken across the mucosal barrier, while microparticles 
were predominantly localized in the epithelial lining[235]. 
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Cells lacking the phagocytosis pathway were shown to accumulate latex beads as 
large as 500nm[236]. Those beads with sizes up to 200nm were shown to be taken up via 
clathrin-mediated pathways, though in a size dependant manner: beads ranging from 
50nm and 100nm showed kinetics resembling those of native ligands, showing little 
hindrance to the process, while beads as large as 200nm were significantly slowed. 
Larger beads with diameters of 500nm were thought to taken up through caveolae-
mediated endocytosis. 
It is possible for cells to internalize particles through multiple mechanisms: In 
one study involving the internalization of latex beads in mouse macrophages, particles 
from 0.2-3µm were shown to be successfully taken up in a size-dependant manner, 
though as size increased, the particles became less dependent on clathrin-mediated 
endocytosis and more dependent on phagocytosis for uptake[232]. This size-dependency 
resulted not only in diminished accumulation of particles as size increased, but also in 
increasing lag times between incubation and uptake. Similar time lags have also been 
observed in viral particles and polyplexes as well[237, 238]. 
Targeted 
The majority of coated vessels are less than 100nm in size, with clathrin-mediated 
endosomes typically having diameters ~100nm[85, 239]. Therefore, it has been 
considered that drug carrier utilizing this pathway should have a diameter of <100nm to 
be internalized. However, there have cases that report successful internalization of 
larger particles. Larger viruses and pathogenic bacteria have been shown to utilize 
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clathrin-mediated endocytosis [240-242]. Particles as large as 1µm coated with either β1-
integrin or epidermal growth factor have been shown to internalize into cells in a 
clathrin-dependent manner. Tf-conjugated polystyrene particles with diameters of 
216nm have proven to form effective anti-cancer devices, carrying doxorubicin to and 
producing toxicity in tumor cells[243].  
Similar results have been observed in vivo in liposomes targeted the transferrin 
pathway, where 60-80nm particles accumulated at a faster rate in the liver and brain of 
rat specimens compared to 140-160nm liposomes[244]; This trend, however, was not 
observed in the brain and heart organs, indicating that size-dependency is not only 
pathway specific, but cell and tissue specific as well. Another independent study of 
liposomes coated with Tf noted that the liposomes were internalized more slowly that 
unmodified Tf[152]. The accumulation of these liposomes in xenograft mouse models 
was found to decrease as liposome size increased from 60nm to 400nm[245]. 
2.4.3 Importance of Size Distribution 
Polydisperse samples can complicate comparisons of samples with different 
average sizes, as their distributions may overlap, rendering it difficult to ascertain the 
relationship between effect and size[216]. In the few studies that have focused on size as 
a major variable in nanoparticle biodistribution, high PdI values of 0.3-0.6 were 
used[246-248], while others failed to mention them entirely[249]. 
Polydisperse samples also create an uneven distribution of the encapsulated 
drug amongst the particles, since larger particles, through fewer in number, will carry a 
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disproportionally higher percentage of the total therapeutic. In cases where the uptake 
or transport is found to be either dependent on size or limited by capacity, this would 
prevent or hinder a significant portion of the drug to be transported. This has been 
reported as the cause for substandard performances in both passive and RME-targeted 
nanoparticle systems[173, 246]. 
2.5 Characterizing Drug-Delivery Performance 
There are varieties of in vitro and in vivo methods used for assessing the 
performance of therapeutic transport across monolayers. Below is a non-exhaustive list 
of commonly used methods that have been referenced in drug delivery systems utilizing 
RME, focusing on examples with transferrin as the ligand. 
In vitro experimental protocols using GI tract and BBB cell lines are most 
commonly grown on permeable supports in microtiter plates with pores large enough to 
allow larger solutes and to travel across freely but small enough to provide a growing 
matrix for the cells (Figure 2-5). One of the most common cell lines used is the 
absorptive Caco-2 lines, a cancer line derived from the colon which differentiate to 
display functional and morphological similarities to the human intestinal epithelium, 
such as developing microvilli and brush boarder enzymes[250]. In addition, Caco-2 cell 
cultures develop a Tf-receptor distribution similar to that in the human GI tract[251]. 
Due to the difficulty in harvesting and developing a continuous cell line from the BBB, 
the Madin-Darby canine kidney (MDCK) cells line is often substituted for BBB, in 
addition to the Caco-2 line, due the biological similarities between GI tract and BBB[252]. 
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Figure 2-5: Transwell® permeable supports[253] 
 
 
 
In these experiments, the cells grow into monolayers that divide the well into 
"apical" and "basolateral" sides. The ability of drugs to traverse these monolayers is often 
described by measuring the apparent permeability, Papp, a reduced form of Fick's first 
law: 
Eq. 2-3: ௔ܲ௣௣ = ௗொௗ௧
ଵ
஼బ஺ 
Here, dQ/dt is the accumulation of the drug in the basolateral chamber over time, 
A the cross-sectional area, and C0 the starting concentration in the apical side. The Papp of 
insulin has been shown to increase significantly when conjugated with transferrin[161, 
162]. A more simple analysis, but also dose-normalized, is to report the percentage of the 
initial dose (therapeutic or nanoparticle) transported[248]. Measurements that are more 
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absolute simply report the total accumulation of the conjugate/nanoparticles in the 
basolateral chamber[161, 172, 223]. 
In vivo measurements mirror many of the latter examples, such as percent 
transported and drug accumulation[169, 254, 255]. More often, the response of the drug 
is measured, rather than the drug directly, which introduces many specialized 
assessment methods (e.g. body weight gain for growth hormones[256], maximally 
possible effect (%MPE) for opioids[164], change in blood-glucose for insulin[160]). In 
oral delivery research, where the goal is to reach the efficacy of standard subcutaneous 
or intravenous administration, bioavailability is often used: 
Eq. 2-4: ܤ݅݋ܽݒ݈ܾ݈ܽ݅ܽ݅݅ݐݕ = ஺௎஼ಲ ஽௢௦௘ಲ⁄஺௎஼ಳ ஽௢௦௘ಳ⁄ × 100% 
This is a measure of the dose-normalized efficacy of a drug (calculated from the 
area-under-the-curve, AUC, of a response vs. time plot) relative to the same drug in a 
different formulation or administered through a different route. This method has been 
used to measure the GI transport of both drug-ligand conjugates[172] and nanoparticle-
ligand systems[163, 173]. Drug delivery across the BBB uses a similar assessment 
method, called the brain uptake index (BUI), which is a measure of the brain uptake of a 
drug relative to a test compound, normalized with respect to each injected dose. 
Typically, a mixture of a radiolabeled test compound and reference compound, usually 
[14C]butanol or [3H2O]H2O, are injected into the test model, followed by rapid sampling 
of the brain tissue. The BUI is given as: 
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Eq. 2-5: ܤܷܫ = ஻௥௔௜௡ಲ/ூ௡௝௘௖௧௘ௗಲ஻௥௔௜௡ಳ/ூ௡௝௘௖௧௘ௗಳ × 100% 
where the test compound has the label "A" and the reference compound "B"[257, 
258]. 
Normalizing the transport or response of a therapeutic, as seen in the Papp term, 
"percent transported", and in bioavailability, is useful in cases where poor permeability 
is expected and higher drug concentrations are required to obtain a measurable 
response[259]. It also allows for comparisons across a variety of experimental methods. 
In all cases, the RME-drug systems are compared to the transport of the native drug, the 
non-targeted nanoparticle, or both, to show the improvement on the delivery method. 
This is often expressed as a ratio of the previously mentioned characterization methods 
(i.e. "insulin-Tf transport was 5- to 15-fold higher than free insulin transport across Caco-
2 cells"[260]), and is often reserved for the concluding remarks the study. 
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Chapter 3: Research Aims 
The main objective of this research is find a suitable benchmark for success for 
drug delivery devices utilizing receptor-mediated endocytosis (RME) to enhance 
transport across biological barriers. Typically, experimental or novel drug delivery 
devices are compared against the conventional drug formulation or route of 
administration. This helps answer the question "how well do these devices improve the 
uptake or response of the therapeutic?" However, the therapeutics in these cases are 
simply cargo traveling with the ligand, and the relative efficacy of a drug compared to 
the drug travelling along these pathways gives no indication of ligand performance or 
potential. Therefore, we propose an alternative question: "What are the therapeutic 
transport capabilities of the RME pathway?" 
To answer this, a priority was made to develop a pharmacokinetic model that 
would provide a mechanistic understanding of the endosomal process. Ligand/receptor 
pathways already receive a significant amount of focus in research, and it was believed 
that existing models in literature could be adapted for these purposes and elucidate the 
governing parameters of transcytosis drug transport. We further hypothesized that the 
transport potential of a ligand alone would be a suitable benchmark for ligand-
therapeutic conjugates and more complex ligand-nanoparticle delivery devices. This 
would be evaluated using a representative ligand, transferrin (Tf). 
In addition, it is generally accepted that large, nanoparticulate devices put strain 
on cellular internalization processes, including endocytosis, but the exact effect size and 
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size distribution have is poorly understood. Contrasting this is the ability of nanoparticle 
to significantly amplify the payload potential of receptor pathways. Our objective is to 
determine how the transport of nanoparticle-ligand delivery vehicles compare to that of 
the ligand itself. 
The specific aims of this work are: 
 
Specific Aim #1: Develop a pharmacokinetic model based on RME-models in 
literature for the transferrin ligand. Determine relevant parameters for transcytosis drug 
transport. 
Specific Aim #2: Evaluate the performance of transferrin in the context of drug 
transport studies using common assessment methods. Use model simulations to 
illustrate role of ligand/receptor pathways during drug transport. 
Specific Aim #3: Determine the effect of size and size distribution of 
nanoparticles on the receptor-mediated pathway. 
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Chapter 4: Development of RME-Transport Barrier Model 
4.1 Introduction 
Ligand-receptor systems have proven to be part of successful strategies for site-
specific, intracellular, and transcellular drug delivery methods. Understandably, there 
have been recent efforts to gain or utilize existing knowledge of intracellular sorting and 
recycling pathways for various cell and receptor combinations to better understand the 
mechanics that govern the delivery and transport of these ligand-therapeutic systems, 
and in doing so, maximize the potential of this emerging technology. 
One of the most commonly used approaches for modeling biological systems is 
to outline discrete steps in terms of ordinary differential equations (ODEs)[261]. This 
method is widely used to describe the receptor-mediated process, with notable examples 
seen in studies involving the transferrin receptor[262], folic acid[263], low-density 
lipoprotein[264, 265], and epidermal growth factor (EGF)[266, 267]. Such models vary in 
complexity depending on their intended use. Detailed models, such as those for EGF 
which outline 25 or even 125 discrete steps[268, 269], provide a comprehensive and 
systematic understanding of the biomechanics of an entire ligand-receptor cycle. 
However, the large number of fitting parameters required in these cases tend to result in 
poorer performance in pharmacokinetic analyses, which prefer reduced models[270]. In 
the case of EGF, many of the underlying steps can be combined into a simpler 7-step 
process[271], focusing the model on the parameters relevant to the efficacy of the ligand 
therapeutic.  
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Krippendorf et al. recognized this need for reduced pharmacokinetic models and 
developed a mathematical framework, based on the EGF cycle, for analyzing receptor-
mediated therapeutics (i.e. therapeutics that themselves act on cellular receptors)[270]. 
In this chapter, we are attempting to adapt such models for monolayers, such as the 
barriers found in the GI tract and BBB, using transferrin (Tf) as a representative ligand 
due to its extensive use in this field. The purpose of this model is to track the various Tf-
cycle species that would have been difficult to quantify experimentally. Experimental 
methods for counting surface receptor-bound ligands requires acid-treatment of the 
cells[272], and receptor quantification requires cell lysing[273], both being experimental 
end points. Quantifying internalized compounds requires steady state conditions and a 
combination of energy inhibitors[262]. It was believed that the ability to follow each 
species during a hypothetical RME-drug transport scenario would shed valuable insight 
on the mechanisms responsible for promoting or hindering future applications. Future 
transport studies would then be based around the mechanisms found to be relevant to 
the transport of therapeutics in this chapter. 
4.2 Materials and Methods 
4.2.1 Materials 
Anti-transferrin (human) in rabbit, IgG antibody was purchased from 
Polysciences, Inc. (Warrington, PA). Human transferrin (Tf) and all other chemical 
reagents were purchased from Sigma Chemical Co. (St. Louis, MO). Non-reagent 
components were purchased from Fisher Scientific (Pittsburgh, PA).  
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Tf-iron saturation was performed according to the method developed by 
Klausner et al.[273] and confirmed using a Tecan Infinite M500 plate reader (Männedorf, 
Switzerland). All samples with an A465/A280 ratio above 0.045 were considered iron-
saturated. Biotin labeling was achieved using the NHS-biotin reagent, as outlined 
previously[120]. Briefly, Tf was dissolved in a phosphate buffer (0.1M sodium 
phosphate, 0.15M NaCl, pH 7.5) at 5mg/ml. NHS-Biotin was added at a 15x molar excess 
and reacted for 60min at room temperature. The reaction was then purified using gel 
filtration columns. Biotin content was analyzed using the HABA assay[274] and 
typically ranged from 3-5mol biotin/mol Tf.  
Buffers and components for cell culture media were obtained from Invitrogen 
(Green Island, New York), with the exception of fetal bovine serum (FBS), which was 
obtained from Gemini Bio-Products (West Sacramento, California). 
4.2.2 Cell culture 
All experiments were performed using Caco-2 cells obtained from Sigma Aldrich 
with passage number ranging from 45-55. Cells were grown in 75cm2 T-flasks in a media 
consisting of Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS and 1% non-
essential amino acids. When cells had reached 80% confluency, they were collected 
using a 0.05% trypsin-EDTA solution for the binding studies or seeded for the transport 
studies. For the transport studies, 12-well Corning (Tewksbury, Massachusetts) 
Transwell® plates with 0.4µm pores were seeded with approximately 50,000 cells. Cells 
were fed every other or third day. Tight junction development was monitored by 
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measuring the trans-epithelial electrical resistance (TEER) with an epithelial 
voltohmmeter (EVOM2, World Precision Instruments, West Haven, CT). TEER values 
typically plateaued after three weeks, around 800 Ω·cm2, indicating fully developed 
tight junctions. 
4.2.3 Receptor-Density Studies 
Kinetic binding data was obtained according to the procedure outlined by 
Vieira[275]. Briefly, various concentrations of Tf-biotin were incubated with Caco-2 cells 
at 4°C in a HEPES buffer (20mM HEPES-NaOH, 100mM NaCl, 0.1% BSA, pH 7.5) until 
receptor binding reached equilibrium, about 4hrs. A low temperatures buffer was used 
to halt the endocytosis cycle and ensure only surface-bound receptors were 
counted[276]. Control samples, representing binding not specific to the Tf receptor, 
received a 100x molar excess of unlabeled Tf. The cells were then quickly centrifuged 
and washed repeatedly with ice-cold buffer, until no un-bound Tf remained. The cells 
were then treated with a lysing solution (1mM EDTA, 50mM NaCl, 10mM Tris-HCl, 
0.1% SDS, 1% Triton X-100, 0.2% BSA, pH 7.4). The lysate solution was then analyzed 
using the avidin/biotin ELISA assay outlined in the same procedure to determine bound 
Tf. Specific binding, or binding associated with the Tf receptor, was calculated from the 
difference between total binding and control samples. 
The association constant and binding-site density were calculated using non-
linear regression analysis using the following model[277, 278]: 
76 
 
Eq. 4-1: ܻ = ஻೘ೌೣ∙௑௑ାଵ ௄ೌൗ  
Here, Y represents the amount of receptor-bound Tf, X the concentration of total 
Tf in the incubation media, Bmax the concentration of binding sites, and Ka the association 
constant 
4.2.4 Avidin-Biotin ELISA 
ELISA plates were created using the procedure developed by Vieira[275] with 
some modifications[279-281]. First, a 10mg/ml stock solution of the anti-Tf antibody was 
diluted with a 50mM NaHCO3 (pH 9.6) in a 1:12,000 ratio. 200µl of the solution was 
added to 96-well plates (Thermo-Scientific Nunc Maxisorp, Waltham, MA) and 
incubated at overnight at 4°C. The plates were then rinsed three times with PBS. 200µl of 
a blocking buffer (1% BSA) was then added and incubated overnight at 4°C. The plates 
were then rinsed three times with PBS. Plates not used immediately were stored with 
their wells filled with PBS with sodium azide. 200µl of samples and standards were then 
added to the wells and incubated at 37°C for 2hrs. The plates were then washed 5x with 
PBS. 200µl of a streptavidin-conjugated peroxidase solution (1mg/ml diluted 1:50,000 in 
0.1% BSA in PBS) was added to the plate and placed on an orbital plate shaker for 90min 
at 120rpms at room temperature. The plates were then rinsed five times with PBS. 200µl 
of a peroxide substrate solution (50mM Na2HPO4, 30mM citric acid, 40mg/ml o-
phenylenediamine, 0.04% v/v H2O2, pH 5) was added and placed on an orbital plate 
shaker for approximately 60min at 120rpms at room temperature. A Tecan M200 plate 
reader reading at 450nm was then used to read the absorbance of the solution.  
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4.2.5 Transport Studies 
Prior to the start of transport studies, culture media were removed from the 
Transwell trays and the wells washed three times with Hanks Buffered Saline Solution 
(HBSS). The cells were then incubated with HBSS for 1hr to deplete intracellular Tf 
levels leftover from the serum, after which the buffer was then removed. For apical-to-
basolateral studies, fresh HBSS was added to the basolateral chamber of the wells, while 
HBSS with 10µg/ml Tf-biotin was added to the apical side. For the basolateral-to-apical 
studies, the solutions were reversed. Control samples contained a 100x molar excess of 
unlabeled Tf. Samples were then taken at 30min, 60min, 90min, 120min, 180min, and 
240min time points, with fresh HBSS added to replenish the sampled amount. The 
studies were completed at 37°C. 
4.2.6 Statistical Analysis 
The results of each study are reported and plotted as the mean ± one standard 
deviation. Statistical differences were determined using ANOVA followed by post-hoc 
comparison testing to determine differences between means. p values of <0.05 were 
considered significant.  
4.3 Development of Transport Model 
Here, we have adopted the outline of a reduced RME-model developed by 
Krippendorf et al. for the transferrin cycle in a cell monolayer geometry[270]. The steps 
described by Ciechanover et al. are listed as follows[282]: iron-saturated Tf (Tf-Fe) binds 
with the surface receptor (TfR); The Tf-TfR complex then becomes internalized, creating 
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an endosome; The higher pH of the endosome compartment causes Tf-Fe to shed its iron 
molecules, which are deposited within the cell; The endosome then returns to the cell 
surface, where the iron-free Tf is released to be recycled.  
Unlike previous models, the geometry and "gate" function of the monolayer 
creates distinguishable apical and basolateral processes and species, designated with "A" 
and "B" subscript in our adaptation in figure 4-1. Here, the initial binding of Tf-Fe [L+] 
and reversible release occurs at step (1) on the apical side and step (6) of the basolateral 
side, creating the complex [RL+]. These are then internalized in step (2) and (7), where 
the internalized complex [RL+]i sheds the iron molecules through step (3), becoming 
[RL]i. The surface recycling step occurs in step (4) for the apical side and step (8) for the 
basolateral. Non-ferrous Tf, [L], is then released in step (5) and (9). In addition, Tf 
receptors are generated and degraded on both sides in step (10) (apical) and step (11) 
(basolateral). 
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Figure 4-1: Transferrin cycle in a cell monolayer geometry 
 
 
 
Rate equations are derived to track the change of the various molecular species. 
For instance, the binding of apical Tf-Fe to its receptors in step (1) is written as follows: 
Eq. 4-2: [ܴ]஺ + [ܮା]஺
௞భ,௞షభርۛ ሮۛ [ܴܮା]஺ 
Reaction rates are then applied for the forward and reverse steps, and 
incorporated into ordinary differential equations (ODEs) for each species. For the rate 
equation of apical Tf-Fe, this is: 
Apical
Basolateral
k-1
k3
k2
k1
k-5
k-4
k7
k6
k-8
k-9
[L+]A
[RL+]A[R]A
[RL+]i
[RL+]B[R]B
[L+]B
[L]A
[RL]A[R]A
[RL]i
[RL]B[R]B
[L]B
k-6
k10
k11
80 
 
Eq. 4-3: ௗ[௅
శ]ಲ
ௗ௧ = −݇ଵ[ܴ]஺
[௅శ]ಲ
௏ಲேಲ + ݇ିଵ[ܴܮ
ା]஺ 
All species are expressed in terms of molecules, and the terms VA, which is the 
volume of the apical chamber, and NA, Avogadro's number, are included to express the 
free ligand as a concentration. All reactions are first-order, with the exception of the 
second-order forward binding steps of Tf-Fe and the zero-order receptor 
degradation/synthesis steps. 
Rate constants were obtained from studies of the Tf cycle on the human 
hematoma line HepG2[26, 27], and are listed in table 4-1. The starting conditions were 
chosen to simulate a typical unidirectional transport study[28]. Ligand-Receptor binding 
studies were performed to determine the starting concentration of binding sites. The 
ODEs are then solved simultaneously using numerical integration if a number of 
assumptions are made: (1) the rate kinetics obtained from literature are similar to the 
those of the cells used in this study, (2) the receptor pool is split evenly between both 
sides, and (3) there is no receptor degradation or synthesis over the course of a transport 
study (the number of binding sites remains constant). The validity of these assumption 
will be discussed when comparing experimental and modeling data. 
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Table 4-1: Kinetic Parameters 
Parameter Rate constant Value 
Binding of [L+] 1k , 6k  (mol-1 min-1) 3.02 x 106 
Dissociation of [RL+] 1−k , 6−k  (min-1) 0.09 
Internalization of 2k , 7k  (min-1) 0.20 
Loss of irona 3k (min-1) 0.28 
Recycling of [RL]ia 4−k , 8−k  (mol-1 min-1) 0.28 
Dissociation of [LR] 5−k , 9−k (min-1) 2.6 
Deg/syn of [R] 
10k , 11k  (molecules min-1) 0 
aFrom Ciechanover et al.[262], The iron-loss and recycling step are known to 
combine so that 1 0.14ൗ = 1 ݇ଷൗ +
1 ݇ିସൗ . These rates were assumed to be equal 
for the sake of the simulation. 
 
 
 
4.4 Results 
4.4.1 Receptor-Density Study 
Figure 4-2 presents the equilibrium binding data of Tf with Caco-2 cells. Non-
specific binding in control samples, representing binding through means other than the 
Tf receptor, increased in proportion with increasing concentration, while specific 
binding, the difference between the total Tf detected and control samples, leveled off. 
Non-linear regression analysis of the binding model (Eq. 1) was used to determine both 
the affinity of the ligand to the receptor, via the association constant Ka, and the binding 
site concentration. The association constant was calculated to be 1.2x108 M-1. The 
binding-site concentration, combined with the known concentration of cells in the 
binding solution, produced a binding site density of 1.08x106/cell. For a 12-well transport 
tray containing approximately 386,000 cells when confluent and fully developed, this 
would result 323fmol of binding sites per side of the monolayer. 
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Figure 4-2: Kinetic binding data of Tf to Caco-2 cells with non-linear model fit
 
 
 
4.4.2 Model Simulation 
With all starting conditions accounted for, a monolayer transport simulation was 
performed assuming an apical concentration of Tf-Fe of 10µg/ml, with the results 
plotted in figure 4-3. The amount of free receptors on the apical side is immediately 
depleted at the beginning of the experiment due to the strong affinity and quick binding 
of the ligand at this concentration. The Tf-TfR complexes are then slowly internalized 
within the cells. This produces an initial sharp increase in internalized endosomes until 
after 6min, when the endosome concentration decreases as the recycling process 
becomes significant. Endosomes that accumulate on the basolateral side result in an 
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increase in both basolateral receptors and, once the ligand is released, total basolateral Tf 
concentrations. Accumulation of basolateral Tf continues until apical receptors are 
exhausted, plateauing at 323fmol. Apical Tf, distinct from the original Tf-Fe, also 
accumulates in proportion with basolateral values (not shown in this graph), though 
receptors returning to this side are then free to transport Tf-Fe again. 
 
 
 
 
Figure 4-3: Model simulation of Tf transport across Caco-2 monolayer at 
10µg/ml apical concentration 
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4.4.2.1 Assumption of Receptor Synthesis and Degradation 
Model Simulations were performed with non-zero values for the receptor 
degradation/synthesis rate constants, k10 and k11, to determine the effect of these steps on 
basolateral Tf transport. The comparison of these simulations and the experimental 
transport studies would determine the validity of the assumption that the receptor pool 
remains constant during the duration of the transport experiments.  
Receptor production steps were included at the cell wall, which is represented in 
the differential equation for the net change in apical receptors at the wall, such as that 
for the apical side here: 
Eq. 4-4 : 
[ ] [ ] [ ] [ ] [ ] 1025211 kRLkRLkVN
RLk
dt
Rd
AA
A
AAA +++−=
−
+
−
+
 
Like other processes that occur at the cell wall for a monolayer geometry, a 
symmetric and proportional step occurs at the basolateral side, which is where step (11) 
occurs. Positive kinetic values represent an overall net increase of receptors, while 
negative kinetic values result in a net decrease in receptors.  
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Figure 4-4: Assumption of Receptor Synthesis/Degradation Kinetic Values 
 
 
 
The effect of receptor production or degradation on the basolateral transport 
over time is plotted in figure 4-4. As noted in figure 4-3, a zero value  for k10 and k11 
produces in no net change in overall receptor levels, and is a reproduction of the result 
in figure 4-3. Positive values of k=100,000 and k=500,000 receptors/min  resulted in 
increased basolateral Tf transport of 344fmol and 414fmol, respectively, a net increase of 
5.3% and 26.8% from the k=0 value. To achieve similar drops in transport, kinetic values 
required negative values of k=200,000 receptors/min (308fmol) and k=2,000,000 
receptors/min (237fmol). 
4.4.2.2 Assumption of Receptor Distribution 
Model simulations were performed with different apical-to-basolateral receptor 
distribution ratios to determine the effect of these ratios have on the basolateral 
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transport capabilities of cellular monolayers. The resulting basolateral Tf levels in these 
simulations are plotted in figure 4-5. The comparisons of these results with experimental 
transport studies would help determine the validity of the assumption that the total 
receptor pool is evenly divided between the apical and basolateral sides.  
 
 
 
Figure 4-5: Assumption of Receptor Distribution Ratios. Ratios are expressed as 
Apical:Distribution 
 
 
 
The original assumption that the receptor pool is split 50:50 between the two 
sides is the same result as the original simulation is figure 4-3, which had a maximum 
basolateral Tf level of 323fmol. Ratio splits that favored higher apical levels produced 
higher basolateral Tf levels, with the 60:40 split resulting in 391fmol and the 70:30 split 
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produced lower transported Tf levels, with a 40:60 ratio resulting in 261fmol and a 30:70 
ratio 196fmol. 
4.4.3.1 Forward and Reverse Transport Studies 
In vitro transport studies were conducted with the same starting conditions as 
model simulations, travelling from the apical to the basolateral side, alongside control 
samples with 100x-fold excess unlabeled Tf-Fe. In addition, studies measuring the 
transport in the reverse direction, from the basolateral chamber to the apical chamber, 
were conducted. The results of these studies were plotted in figure 4-6 and figure 4-7, 
and a summary of their results and analysis are compiled in table 4-2. 
 
 
 
 
Figure 4-6: Apical-to-basolateral transferrin transport 
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Figure 4-7: Basolateral-to-apical transferrin transport 
 
 
 
In all studies, control samples indicated non-specific transport increased linearly 
with respect to time. Total transport was found to be significantly different at all time 
points from the control samples for all studies. Specific transport, the difference between 
total transport and the control samples, increased sharply beginning at the 30min mark, 
before maximizing around 2hrs and reaching a plateau. 
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Table 4-2: Transport Results Summary 
 Apical-to-
Basolateral 
Basolateral-to-
Apical 
Transport (fmol)     
Total - 4hr   344±27  354±42 
Specific  299±31  293±46 
Non-Specific - 4hr  45±15  62±20 
Analysis     
Papp (10-8 cm/s)  2.9±0.8  3.8±1.5 
 
 
 
Model Simulations reflected the same trend as indicated in the experimental 
values for specific transport. However, experimental values for transcytosis 
accumulation showed a lag of approximately 0.5hr compared to the model. To correct 
this, a Δt=0.5hr was incorporated into transported values. In addition, the plateau level 
was below the value predicted by the receptor-density study (320fmol). Since model 
simulations showed that apical receptor levels correlated with basolateral Tf transport, 
this was also corrected in our model. The results of the updated model accounting for 
these corrections is plotted for the apical-to-basolateral experiment in figure 4-8. 
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Figure 4-8: In Vitro Transport of Transferrin Across Caco-2 Monolayers - Model 
Corrections 
 
 
 
4.5 Discussion 
4.5.1 Assumption of Constant Receptor Levels 
Previous models of RME-transport of cells in suspension assumed that receptor 
degradation and synthesis is negligible during the course of short-term experiments[262-
264, 267, 270]. While this assumption was considered valid for these transport 
experiments, model simulations were carried out with non-zero degradation/synthesis 
rate constants to determine if this could be observed from data collected during in vitro 
transport experiments. Positive rate constants, indicating a net increase in overall 
receptor counts from higher synthesis rates compared to degradations rates, resulted in 
a deviation from the expected plateau effect once initial apical receptors had been 
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depleted. This is due to newly available receptors, synthesized during and after the 
initial pool had been depleted, carrying additional Tf across the monolayer. Total 
basolateral RME transport can thus be approximated using the following equation: 
Eq. 4-5: [௅]ಳௗ௧ ≈ [ܴ]஺,௧ୀ଴ + ݇ଵ଴ 
On the other hand, when there is a net decrease in overall receptor availability 
due to higher degradations rates compared to syntheses, basolateral transport is 
hindered due to a reduction in available receptors. However, the plateau effect is still 
observed since a negative growth in receptors does not produce a negative transport 
rate. This means that the approximation of Eq. 4-5 is invalid when receptor degradation 
rates are high. Furthermore, while newly synthesized receptors are available to transport 
ligands across the monolayer at any time, receptors must degrade before transport 
occurs to have an effect. Because of this, in order to achieve the same ±5% change in 
basolateral transport degradation rates needed to be doubled the synthesis rate (-200,000 
vs. 100,000 receptors/min), and quadrupled to achieve a comparable ±25% change.  
The in vitro transport studies conducted and shown in figure 4-6 indicate no 
significant increase in receptor levels over the course of the experiment. This partly 
provides support for the assumption that receptor levels remain constant during the 
experiment, though it does not rule out the possibility that receptors degrade 
significantly. In fact, this would account for the difference in receptor levels observed 
from the apical-to-basolateral transport studies from what was predicted using the 
receptor-density studies (299±31fmol vs. 326fmol, respectively). However, there are 
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other possible explanations for this drop. First, the receptor-density studies were 
conducted on cells in the log-growth phase, before tight junctions had developed. 
Proliferating cells have been previously shown to have increased Tf-receptors levels, 
presumably due to their higher nutritional iron needs[283, 284]. The transport studies, 
on the other hand, were conducted on cells in the lag phase, when they are no longer 
proliferating. This would result in an overestimate of receptors when using receptor-
binding analyses. Another possible explanation would be due to uneven split ratios 
between the apical and basolateral sides, discussed in the following section. 
4.5.2 Assumption of receptor distributions 
It was assumed for the default model simulations that the total receptor pool was 
split between the apical and basolateral sides evenly. While receptor-density plots are an 
often-used tool for determining receptor concentrations of cells in suspension (where the 
whole cell surface is analyzed), this assumption is unique to a monolayer transport 
system, and had not been taken from literature. To test this assumption, model 
simulations were first performed with multiple receptor distribution ratios, favoring 
both apical and basolateral sides. The simulations showed that basolateral transport is 
solely a function of the available apical receptors. When the distribution favored the 
basolateral side, basolateral Tf transport has reduced due to the diminished apical 
receptor pool; Conversely, if the distribution ratio favored the apical side, basolateral 
transport was increased in a stoichiometric proportional to the increased ratio.  
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Since apical-to-basolateral transport was less than that expected from the 
receptor density studies, we conducted reverse-direction transport studies to determine 
if receptor levels were lower on both sides, or if the receptor distribution favored the 
basolateral side. Specific transport was shown to be diminished on both sides compared 
to model values, with no significant difference between the two sides, indicating that 
receptors are evenly distributed across both sides and validating this assumption. 
However, this test fails to rule out receptor degradation discussed in the previous 
section as a possible explanation for the less-than predicted values. Receptor-density 
studies conducted under these conditions would be necessary to rule this out, and were 
performed in the next chapter. 
4.5.3 Transport studies as RME-transport systems 
Control samples served three purposes: (1) to verify the integrity of the 
monolayer, (2) to distinguish between total and RME transport, and (3) to serve as a 
model for non-specific therapeutic uptake. Control samples resulted in a linear 
accumulation of Tf in the basolateral chamber, indicative of diffusion-based transport. 
The apparent permeability coefficient (Papp) for the apical-to-basolateral and reverse 
direction was on the order of  3x10-8 cm/s. This is below typical monolayer integrity 
markers, such as mannitol (1.2x10-7 cm/s)[285] or lucifer yellow (1x10-6 cm/s)[286], 
indicating that the monolayer integrity was intact and sufficiently prevented excessive 
leakiness. This also permitted these control studies to be used throughout the scope of 
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this research project to represent non-specific transport of therapeutics, which would be 
compared to RME-specific uptake. 
Experimental transport studies were shown to match well with the values 
predicted in model simulations, particularly the plateau effect caused by the exhaustion 
of available receptors. However, experimental values were offset from the model 
simulations by an approximate 30min delay, which was correct through the introduction 
of a time-lag constant, Δt, to match transport results on the opposite side of the dose. 
Time constants have similarly been used as fitting parameters to compensate for 
experimental deviation from theoretical models, such as the delay between antigen 
binding and  as T-cell receptor signaling[287] and the delay between dosing and plasma 
and tissue detection of epidermal growth factor[288] and interferon-β[289] in vivo.  
The cause for this lag is likely due to the fact that apically internalized 
endosomes are not immediately available for basolateral recycling, and undergo further 
mechanisms before undergoing transcytosis. Tf has been found to enter two distinct 
initial endosome populations which may possess different recycling mechanisms, 
though these have not undergone kinetic analyses[290]. Similar lag phenomena have 
been observed and accounted for in models regarding receptor signaling 
transduction[287] and virus pathogenesis[291]. However, these modeling methods are 
used to hide, not explain underlying biological mechanisms[292]. Since the lag did not 
affect the maximum transport potential and does not factor into the assessment methods 
being investigated, this was not investigated further. 
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As our model includes no cellular mechanism for directing an internalized 
endosome to specific sides, simulations show that RME results in transport to both sides 
of the chambers. This is a hindrance to drug delivery devices targeting RME pathways 
across monolayers, because it is undesirable for ligands to return to the apical chamber, 
lowering the efficiency of these devices. However, this is typically not observed or 
reported, as the only distinguishing feature between starting and transported Tf species 
is the presence of iron. Spectroscopy methods lack the sensitivity to detect this, 
particularly at high apical concentrations[293], and labeling compounds are most often 
used to detect only the ligand itself. Radiolabeling methods have previously been used 
in studies of the Tf cycle to distinguish between iron, using the 59Fe isotope, and the 
ligand, using the 125I isotope[294-297], which could be used here to confirm the results of 
the model. In addition, this technique could be used to distinguish between passively 
and RME-transported Tf within the same sample, eliminating the need to perform 
control studies which isolate passive transport separately. 
4.6 Conclusions 
A generalized model for RME pathways developed by Krippendorf  et al. was 
adapted to model the transport of a model ligand, Tf, across biological barriers, like 
those found in the GI tract and BBB. Kinetic rate constant for Tf were obtained from 
studies found in literature, and receptor-density studies for were performed to 
determine the available Tf-receptor pool in the Caco-2 cell line. Using this model, 
simulations of transport studies were able to predict experimental values to within 8% of 
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the observed experimental value before corrections to the starting receptor counts were 
made. This indicates literature models can be successfully utilized to predict and 
potentially choose optimal ligand-receptor pairings, before transport studies are 
pursued. This potentially represents a considerable time-saving measure, as fully-
differentiated cell monolayers take weeks to develop.  
The purpose of the model was to elucidate the important parameters or 
mechanisms responsible for ligand transport that might otherwise be difficult to 
determine experimentally. Simulations, backed by experimental studies, established the 
correlation between receptor availability and basolateral transport capabilities. Thus, 
upper transport limits can be established through receptor-density studies; These 
studies carry the advantage of being able to use cells during the growth phase, enabling 
for faster experiments and larger volumes, and flexibility in culture equipment. High-
throughput screening methods have been extensively used for receptor-ligand binding 
data[298-300], and would ideally be used to screen for more advantageous ligand/cell 
pairings. On the other hand, the fact that experimental transport studies corroborated 
model values demonstrates that they themselves can determine the known receptor 
pools, and even partial kinetic data. Despite the effort required for transport studies, 
they additionally provide other information such as non-specific permeability rates that 
are not provided by receptor-density studies. 
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The presence of a saturable, upper transport limited has significant implications 
for drug delivery and the pharmacokinetics of the drug. In the next chapter, the role of 
this saturation point will be explored in the context of traditional assessment methods. 
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Chapter 5: Ligand Transport in Drug-Delivery Studies 
5.1 Introduction 
In the previous chapter, a pharmacokinetic model was adapted from existing 
literature models for accommodate biological barriers. Such models have previously 
been used to successfully predict the cellular uptake, disposition, and clearance of 
receptor-targeting therapeutics. In the case of RME-drug delivery vehicles intended to 
improve GI tract or BBB transcytosis, the drug is not intended to have a therapeutic 
effect at the monolayer; instead, the drug is tied to the kinetics of the endosomal cycle 
belonging to the ligand. For this reason, these therapeutic-ligand complexes are referred 
to as "Trojan horses"[301].  
Previously, the transport of therapeutics across the GI tract and BBB have been 
reported using a variety of assessment methods. In vitro methods using cultured 
monolayers and specialized Transwell® plates typically report the apparent 
permeability (Papp) or the percentage of the apically-applied dose[161, 162, 248, 260]. In 
vivo studies use these in addition to more unique calculations, such as bioavailability 
(oral-delivery) [163, 172, 173], the brain-uptake index (BUI) [257, 258], or the therapeutic 
effect of the drug[160, 164, 256]. A common trait among these assessment methods is the 
normalization of the measurement with respect to the initial dose. This has many 
advantages, as it enables results from different labs or experimental models (for 
instance, using different animal species) to be compared. In addition, in cases where 
transport is expected to be poor, higher doses than control samples are often used to 
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induce a measurable therapeutic effect, and dose normalization allows for the two to be 
compared[259]. 
In this chapter, we investigate the impacts the addition of pharmacokinetic 
cycles, separate from those of the therapeutic (in this case, the role of the ligand, have on 
the assessment methods discussed above. In particular, the use of dose-normalization in 
the presence of an upper transport limit due the restraints of the available receptor pool 
will be studied. As this limit is realized in cases where all receptors are utilized, the 
effect of continuous receptor saturation under short and long-term scenarios will also be 
investigated.  
5.2 Materials and Methods 
5.2.1 Materials 
Anti-transferrin (human) in rabbit, IgG antibody was purchased from 
Polysciences, Inc. (Warrington, PA). Human transferrin (Tf) and all other chemical 
reagents were purchased from Sigma Chemical Co. (St. Louis, MO). Non-reagent 
components were purchased from Fisher Scientific (Pittsburgh, PA).  
Tf-iron saturation was performed according to the method developed by 
Klausner et al.[273] and confirmed using a Tecan Infinite M500 plate reader (Männedorf, 
Switzerland). All samples with an A465/A280 ratio above 0.045 were considered iron-
saturated. Biotin labeling was achieved using the NHS-biotin reagent, as outlined 
previously[120]. Briefly, Tf was dissolved in a phosphate buffer (0.1M sodium 
phosphate, 0.15M NaCl, pH 7.5) at 5mg/ml. NHS-Biotin was added at a 15x molar excess 
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and reacted for 60min at room temperature. The reaction was then purified using gel 
filtration columns. Biotin content was analyzed using the HABA assay[274] and 
typically ranged from 3-5mol biotin/mol Tf.  
Buffers and components for cell culture media were obtained from Invitrogen 
(Green Island, New York), with the exception of fetal bovine serum (FBS), which was 
obtained from Gemini Bio-Products (West Sacramento, California). 
5.2.2 Cell culture 
All experiments were performed using Caco-2 cells obtained from Sigma Aldrich 
with passage number ranging from 45-55. Cells were grown in 75cm2 T-flasks in a media 
consisting of Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS and 1% non-
essential amino acids, except where noted. When cells had reached 80% confluency, they 
were collected using a 0.05% trypsin-EDTA solution for the binding studies or seeded 
for the transport studies. For the transport studies, 12-well Corning (Tewksbury, 
Massachusetts) Transwell® plates with 0.4µm pores were seeded with approximately 
50,000 cells. Cells were fed every other or third day. Tight junction development was 
monitored by measuring the trans-epithelial electrical resistance (TEER) with an 
epithelial voltohmmeter (EVOM2, World Precision Instruments, West Haven, CT). TEER 
values typically plateaued after three weeks, around 800 Ω·cm2, indicating fully 
developed tight junctions.  
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5.2.3 Receptor-Density Studies 
Kinetic binding data was obtained as previously outline in section 4.2.3 and 4.2.4 
for both short and long-term studies. Short-term studies were designed to mimic the 
feeding conditions of their short-term transport analogous, and were prepared as 
follows: Cells were harvested at 80% confluency using a trypsin/EDTA solution 
(Invitrogen, Green Island, New York), and washed in PBS. They were then incubated in 
a solution of 10µg/ml Tf in HBSS for a period of 4hrs. After washing the cells, the cells 
were incubated in the feeding media for 2hrs, followed by additional wash steps, 
followed by 1hr incubation in HBSS to withdrawn all intracellular Tf. All steps occurred 
at 37°C. The cells were washed a final time before commencing with the binding studies.  
Long-term receptor-density studies were designed to mimic the incubation steps 
of a long-term transport study. To accomplish this, Caco-2 cells were grown in T-flasks 
with a modified growth media that included an additional Tf concentration of 10µg/ml. 
Cells were split and reseeded in the growth flasks for a period of three weeks, the 
approximate time cells need to develop tight junctions when grown in Transwell® 
plates. Cells were then harvested and used in binding studies as previously outlined. 
5.2.4 Transport Studies 
Prior to the start of transport studies, culture media were removed from the 
Transwell® trays and the wells washed three times with Hanks Buffered Saline Solution 
(HBSS). The cells were then incubated with HBSS for 1hr to deplete intracellular Tf 
levels leftover from the serum, after which the buffer was then removed. Fresh HBSS 
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was added to the basolateral chamber of the wells, while HBSS with Tf-biotin was added 
to the apical side. Apical concentrations were either 50µg/ml or 1µg/ml (data includes 
the 10µg/ml sample from section 4.2.5), and control samples contained a 100x molar 
excess of unlabeled Tf. Samples were then taken at 30min, 60min, 90min, 120min, 
180min, and 240min time points, with fresh HBSS added to replenish the sampled 
amount. The studies were completed at 37°C. 
Short-term repeat dose studies were conducted to mimic doses given in quick 
succession, and were performed as follows: Transwell® trays were incubated with HBSS 
containing 10µg/ml Tf-biotin for 4hrs, to mimic a transport study, although no samples 
were taken. The cells were then washed three times and incubated with growth media 
for 2hrs. The cells were washed again, incubated with HBSS for 1hr, and washed a final 
time. The transport study was then conducted as previously described.  
Long-term studies were conducted to mimic continual use of the Tf pathways. To 
accomplish this, cells seeded on Transwell® plates were fed with growth media 
supplemented with Tf at a concentration at 10µg/ml during the period of tight junction 
development, approximately 3 weeks. A repeat of the 10µg/ml transport study was then 
conducted.  
5.2.5 Statistical Analysis 
The results of each study are reported and plotted as the mean ± one standard 
deviation. Statistical differences were determined using ANOVA followed by post-hoc 
comparison testing to determine differences between individual means. Baseline level of 
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significance was chosen to be α≤0.05, and more specific p-values are listed, where 
appropriate. Graphically, levels of significance are noted according to the following 
notation: * - p-value≤0.05; ** - p-value≤0.01; *** - p-value≤0.001. 
5.3 Results 
5.3.1 Dose Study 
As many drug delivery assessment methods assume dose proportionality and 
utilize normalization, we wished to conduct a transport study with a starting apical Tf-
Fe concentration of 1µg/ml and 50µg/ml and compare it to the previous 10µg/ml study. 
The results are plotted in figure 5-1 and figure 5-2. Here, non-specific uptake of the 
1µg/ml study was below our ELISA's detection limit of 10fmol, while uptake of the 
50µg/ml study reached as high as 255±18fmol. Specific RME-transport sharply increased 
in both studies, starting at the time-lag 0.5hr mark, before plateauing after 1.5hr at 
293±20fmol with an apical dose of 1 µg/ml and 308±34 with a 50µg/m apical dose, both 
insignificantly different from the 10µg/ml study. 
 
 
108 
 
Figure 5-1: Transport study at 1µg/ml Tf-Fe 
 
 
 
 
Figure 5-2: Transport study at 50µg/ml Tf-Fe 
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5.3.2 Short-term Repeat Transport Study 
Model simulations indicated that maximum basolateral transport ended with the 
complete polarization of the available receptor pool: receptors initially on the apical side 
were deposited to the basolateral side, resulting in an imbalance of receptor distribution. 
To test how this would impact further transport, repeat studies were conducted with 
short incubation times (figure 5-3) and compared against previous results (figure 4-7). 
Non-specific uptake increased linearly with respect to time, reaching a maximum of 
48±9fmol at 4hr. Maximum transport reached 173±9fmol, while specific RME-transport 
reached a plateau of 126±25fmol, both values significantly lower than the previous 
10µg/ml study. 
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Figure 5-3: Short-term repeat study 
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298fmol receptors are exhausted and transport is halted at around the 1hr, followed by 
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Figure 5-4: Short-Term Repeat Study - Model Simulation. Y-axis shows 
difference from starting apical receptor values. Steps: (1) Initial 4hr transport 
study, (2) 2hr cell media incubation, (3) 1hr HBSS incubation, (4) Repeat 4hr 
transport study 
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Non-linear modeling analysis calculated the association constant, Ka, to be 
1.15x108 M-1, which agreed with our previous result of 1.17x108 M-1. The binding site 
density, calculated to be 1.08x106 sites/cell, also matched that of the initial study 
(1.09x106 sites/cell). A statistical analysis comparing the fits of the two models 
determined they were not significantly different. 
 
 
 
 
Figure 5-5: Ligand-binding data for receptor density analysis: short-term repeat study
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with supplemented human Tf during the tight junction development stage. A transport 
study with an apical concentration of 10µg/ml was then conducted as done previously 
(figure 5-6). Accumulation of Tf via non-specific uptake reached a maximum of 
51±10fmol after 4hrs, while total transport reached a maximum of 300±26fmol. Specific 
RME transport reached a plateau of 247±38fmol after 1.5hrs, a 17% reduction for our 
initial 10µg/ml study. To determine what effects this has on the receptor pool, a receptor 
density study was performed on cells grown in the same supplemental media for the 
same length of time (figure 5-7). Non-linear regression analysis returned new fitting 
parameters, and showed the cells contained 8.82x105 binding sites/cell. Using Fischer's F-
test to test this new  parameter on the original data[302], it was determined that the 18% 
drop in binding sites was significant (p=0.0017). In contrast, the new association 
constant, 1.24x108 M-1, was not significantly different from the original value. 
 
 
 
114 
 
Figure 5-6: Long-term transport study 
 
 
 
Figure 5-7: Ligand-binding data for receptor density analysis: short-term 
repeat study 
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5.4 Discussion 
A summary of the results is presented in table 5-1, along with commonly 
observed assessment methods discussed previously: the percentage of dosed Tf to have 
been transported across via non-specific and combined pathways, the ratio of RME to 
passive transport ratio, and the total to passive transport ratio. 
In comparing the results between the variably dosed studies, we observed 
significant differences in transport among the control studies, though the ratio of their 
transport to the initial dose were close enough to indicate that transport is dose-
proportional. The linear accumulation of the 10µg/ml and 50µg/ml studies is indicative a 
diffusion-governed transport process, which is driven by concentration gradients across 
the monolayer. When the concentration gradients remained unchanged in the repeat 
dose studies, no significant changes in the control values were observed, despite 
observed drops in receptor concentration. This demonstrates that the receptor has no 
influence on non-specific transport across the monolayer.  
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Table 5-1: Transport Assessment     
 Variable Dose Studies Repeat Studies 
    Short-term Long-term
Dose (µg/ml) 10 1 50 10 10 
Transport       
Total (t4hr) (fmol) 344±27 293±20 563±28 173±9 300±26 
RME  (fmol) 298±22 293±20 308±34 126±25* 247±38* 
Passive (t4hr) (fmol) 45±15 <10* 255±18* 48±9 51±10 
Analysis      
% Transported - Passive 0.082 <0.16 0.075 0.077 0.082 
% Transported - Combined 0.52 4.7 0.18 0.20 0.40 
RME/Passive 6.7 >30 1.2 2.6 4.9 
Total/Passive 7.7 >30 2.2 3.6 5.9 
Analyses used total and passive transport values at the 4hr mark 
*Results show a significant difference from high dose study with p<0.01 
 
 
 
In contrast to the non-specific transport observed in the variably dosed studies, 
RME-transport remained unchanged, despite the changes in apical Tf concentration. 
This is because Tf outnumbered available receptors in all cases, making the receptor 
pool the limiting factor in specific transport. This mechanism leads to a lack of dose 
proportionality, and is a common cause for nonlinear pharmacokinetics[303]. Because of 
this influence, the results of the transport studies bear many similarities with the 
binding studies (figure 5-5), despite that binding studies are completed at equilibrium 
conditions with respect to Tf concentration, while transport studies occur over time and 
contain a fixed concentration: In control studies relying on non-specific interactions with 
the cell, Tf passive transport and binding increases linearly as a function of Tf 
concentration, with no influence on receptor concentration; However, once the 
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concentration of the ligand exceeds the concentration of the receptor, specific binding 
plateaus, and the excess ligand remains unused. 
The repeat use of ligand transport was shown to adversely affect the available 
receptor pool on cells, decreasing RME and overall transport. Short-term studies were 
designed to mimic dose-regimens requiring multiple daily uses of RME-drug delivery 
devices. Simulations showed that receptors travel to and from the basolateral side 
during the transport and equilibrium steps, but when equilibrium times were cut short, 
subsequent transport was 42% of its initial amount due to diminished apical receptor 
levels. Muro et al. had similarly found the slow recycling of the adhesion molecule 
ICAM-1 to result in diminished intracellular transport of drug delivery vehicles after 
short, successive dosing, but had believed ligands with faster transit times, like Tf, 
would be immune to this effect[304]. However, due to the geometry of the monolayer 
and the longer than expected transcellular recycling times, this was found not to be the 
case. 
Long-term studies, designed to mimic continuous use of an RME-therapeutic 
system, also resulted in diminished transport (247±38). Previously, cells have shown to 
down-regulate their Tf-receptor levels in iron-rich culture media[271, 305, 306], while 
conversely up-regulating their receptor levels when deprived of iron[307, 308], which 
serves to control the uptake of iron in response to different environmental conditions. 
While short-term polarization of receptors can only occur in monolayer geometries, this 
phenomenon affects surface and intra-cellular targeting devices as well. Thus, the 
118 
 
efficacies of RME-based drug delivery devices are dependent on their dose regiment, 
which influence the availability of receptors. 
The dependence of the receptor in RME-transport processes, while having no 
role in passive ones, produces misleading results when directly comparing the two. 
When calculating the percentage of the available ligand that had been transported across 
the monolayer, the 1µg/ml study appears to have the superior result, despite similar 
performances in the RME transport process. The ratios of RME/passive and total/passive 
transport increases similarly with decreasing dose concentrations because the receptor 
availability remains unchanged. On the other hand, RME-transport levels decreased in 
both short- and long-term repeat studies due to drops in receptor levels, while consistent 
apical ligand concentrations resulted in unchanging passive-transport levels. This also 
produces results that appear inferior to the original 10µg/ml study, according to all three 
assessment methods, despite the studies receiving the same apical dose. 
Furthermore, studies that only observe the total transport of RME-therapeutic 
drug delivery systems without proper controls fail to recognize that this is the result of 
the RME and non-specific pathways occurring in tandem. Comparing these to the 
passive transport of the therapeutics will produce one of two outcomes: if the 
contribution of RME-transport is low, total transport will not appear different from the 
therapeutic alone; if RME-transport is significant, total transport will appear greater 
than the therapeutic. Thus, this method may not only be misleading, but also incapable 
of producing an inferior result.  
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5.5 Conclusions 
In the previous chapter, the ligand-receptor pathways was shown to be capable 
of being saturated when receptor pools were exhausted during transport. This upper 
limit was shown to significantly impact the results of transport assessment methods that 
relied on dose normalization. In studies that varied their dose, ones with lower starting 
apical concentration appear superior to studies with higher doses, despite equal and 
maximal performances for receptor-mediated transport in all cases. In all cases, model 
simulations predicted this, and differences in total transport was due entirely to non-
specific transport mechanisms. 
Despite the ability of model simulation to predict the behavior of RME-transport, 
the effect of continual receptor-saturation was shown to negatively impact transport in 
both the short and long-term: short-term effects were caused by the polarization of the 
receptor pool resulting from prior transport, while long-term saturation initiated 
receptor down-regulation. It is important to note that, while model simulations were 
able to predict changes in receptor pool distribution for short-term repeat studies, this 
was only accomplished when the effects of prior transport was taken into account. These 
particular studies were design to mimic therapeutic requiring multiple daily doses; Even 
with the capability of predicting receptor polarization patterns, this would add 
significant complications to the design of drug regimens for patients. 
Long-term studies were design to simulate the effects of prolonged use of RME-
based therapeutics. In these cases, model simulations did not account for the down-
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regulation of receptor pools, which resulted in decreased transport capabilities. This 
demonstrates the dynamic behavior of cells, and the complexities involved with taking 
advantage of biological mechanisms for reasons other than their intended use. This 
further adds complexity to the design of therapeutic regimens for patients.  
The disagreements among the results in table 4-2 highlight the fallacy in directly 
comparing passively transported therapeutics and RME-based therapeutic systems: 
ligand/receptor systems do not improve the passive uptake of therapeutics across 
monolayers; on the contrary, they occur within separate and independent transport 
routes. In this chapter, we demonstrated how a typical RME-drug delivery device is 
transported across a monolayer through both mechanisms simultaneously: (1) non 
specific-uptake, which occurs in a dose-proportional manner, allowing for the use of 
dose-normalized concentration measurements[309, 310], and (2) the endocytosis 
pathways, which was shown to lack dose-proportionality, and invalidating the 
assumptions inherent in typical assessment methods. The availability of receptors, and 
thus the performance of the delivery device, was further shown to change with repeated 
use of the cycle. Thus, while it is clear that RME systems have the potential to improve 
the overall transport of therapeutics, it is imperative that future research of these devices 
be evaluated within the context of the ligand and receptor's capabilities and 
pharmacokinetics.  
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Chapter 6: Nanoparticle Transport 
6.1. Introduction 
The results of the previous chapter had concluded that the cell's ability to 
transport ligands across the cell through the RME pathway is limited by the receptor 
availability. Though this limit was found to be dynamic and can change with use, 
transport potential was found to be independent of ligand dose. Previously, work 
involving the Vitamin-B12 pathway had noted that, despite the ability to improve 
therapeutic uptake, its limited in vivo uptake capacity in humans prevents ligand-
therapeutic conjugates from being effective[10, 249]. It is believed that this uptake 
capacity is directly linked to the receptor availability. Therefore, the use of drug-ligand 
conjugates, which have a low drug-to-ligand ratio, is limited to cases where the required 
therapeutic dose is less than the targeted monolayers receptor pool. This does not seem 
likely, given the results of prior studies. 
An often-proposed method for increasing the efficacy of RME-pathways is to 
utilize polymeric nanocarriers with therapeutics encapsulated within them. The particles 
have previously proven to provide a number of benefits: The polymer casing can 
provide the therapeutics protection from the harsh environments of the GI tract, 
protecting them from degradation[311]; Since the particle surface will feature the ligand 
coating, this eliminates the need for direct ligand-therapeutic conjugation, which can 
hinder biological interaction of the therapeutic[312]; In addition, particles can be 
designed to feature timed, prolonged, or triggered release mechanisms for more specific 
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therapeutic delivery options[313]. In RME transport, nanoparticles can amplify the 
uptake capacity of RME pathways by carrying a larger cargo than therapeutic-ligand 
conjugates can, with individual nanoparticles capable of carrying thousands of drug 
molecules[163]. The capacity of these particles is a function of their size, with larger 
particles capable of carrying higher amounts of therapeutics than smaller ones[208]. 
Despite the advantages nanoparticle offer, it is widely acknowledged that the 
size of particles places a significant burden on the cell, making it more difficult for 
endosomal vesicles to form. Normal coated vesicles average around ~100nm in diameter 
for clathrin-mediated endocytosis, and ~70nm for caveoli-mediated endocytosis, the two 
most well understood RME pathways[85, 239]. Studies have shown this by comparing 
the endosome internalization rate below and above these sizes[244]. Furthermore, it is 
also understand that the larger the particles these particles are, the greater burden they 
impose on the cell[245]. Because of this, it is thought that smaller particles can act as 
superior drug delivery vehicles; however, since transport is limited by the number of 
apical receptors, the design of RME-particle carriers must weigh the advantages of 
larger payloads with the disadvantage of reduced transport. 
Though particle size is accepted to be an important parameter, size distribution is 
a variable often neglected in literature. The Ishida review cited above, for instance, failed 
to mention the size profiles of the liposomes mentioned. In cases where particle size has 
been a major variable for study, polydisperse samples have been used, indicating 
overlapping size profiles which blur the difference from sample-to-sample[246-248]. 
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This demonstrates a need to evaluate not only the effect of size distribution on particle 
uptake, but to study the effect of particle size in the absence of polydisperse size profiles. 
This chapter focuses on studies designed to determine the potential impact of 
nanoparticles on the endocytosis process in light of the cells limited transport 
capabilities. Two variables were evaluated: (1) the average diameter of the particles, 
when their size distribution was held to a minimum, and (2) the polydispersity of the 
particle samples, when average size was held constant. 
In line with currently held belief that smaller particles are more easily 
transported, we hypothesize that smaller, monodisperse particle samples will come 
closest to reaching the transport threshold determined in the previous chapter, followed 
by increasing larger particles. When considering polydisperse samples, we hypothesize 
that, when comparing samples of similar average sizes, more polydisperse samples will 
suffer diminished transport due to the presence of numerous, smaller particles that 
saturate the receptor pathway, while larger particles, carrying the bulk of the samples 
mass, will suffer from restricted transport. To further investigate the latter hypothesis, 
we will conduct competition studies using bimodal samples mixed from separate, 
monodisperse samples, to determine the mechanism for diminished transport. 
6.2. Materials and Methods 
6.2.1 Materials 
Poly(lactide-co-glycolide) (PLGA, MW= 67,000, co-polymer ratio 50:50) was 
purchased from Lakeshore Biomaterials. Non-reagent poly(ethylene glycol) (PEG, 
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MW=35,000) was purchased from Fluka. Iodine-125 (125I) and Iodine-131 (131I) were 
purchased from Perkin-Elmer (Shelton, CT). Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenyl 
glycoluril; Pierce Thermo Fisher, Rockford, IL) and inert NaI were kindly supplied by 
Dr. Linda Knight. All other chemical reagents were purchased from Sigma Chemical Co. 
(St. Louis, MO). Non-reagent components were purchased from Fisher Scientific 
(Pittsburgh, PA). All water used was deionized by a Millipore water purification system. 
Tf-iron saturation was performed according to the method developed by 
Klausner et al.[273] and confirmed using a Tecan Infinite M500 plate reader (Männedorf, 
Switzerland). All samples with an A465/A280 ratio above 0.045 were considered iron-
saturated. Biotin labeling was achieved using the NHS-biotin reagent, as outlined 
previously[120]. Briefly, Tf was dissolved in a phosphate buffer (0.1M sodium 
phosphate, 0.15M NaCl, pH 7.5) at 5mg/ml. NHS-Biotin was added at a 15x molar excess 
and reacted for 60min at room temperature. The reaction was then purified using gel 
filtration columns. Biotin content was analyzed using the HABA assay[274] and 
typically ranged from 3-5mol biotin/mol Tf.  
Buffers and components for cell culture media were obtained from Invitrogen 
(Green Island, New York), with the exception of fetal bovine serum (FBS), which was 
obtained from Gemini Bio-Products (West Sacramento, California). Substrates from the 
avidin-biotin ELISA, listed previously in section 4.2.4, are used for portions of the 
nanoparticle conjugation procedure. 
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6.2.2 Nanoparticle Fabrication 
Two procedures were used to fabricate nanoparticles in the desired size range: a 
single emulsion procedure, involving mechanical mixing of two immiscible phases, and 
a nanoprecipitation procedure involving the mixing of two miscible phases. 
A single emulsion/solvent evaporation procedure was developed by modifying 
existing double emulsion techniques[314]. Briefly, PLGA was dissolved in either DCM 
or ethyl acetate at 12.5mg/ml. 4ml of this organic phase was emulsified for 2min in 20ml 
of a continuous phase consisting of varying amounts of the surfactant PVA and PEG. 
The emulsification process was performed using either a homogenizer (Polytron® 
System PT3100 homogenizer with PT-DA 3007/2EC dispersing aggregate; Kinematic) at 
20krpms, where only ethyl acetate was used as the solvent, or a sonicator (Hielscher 
UP200s, Hielscher Ultrasonics GmbH) at 20% amplitude, where only DCM was used. 
The choice of solvent was based on initial experimentation that produced nanoparticles 
in our desired size range. The emulsion was then added to an extra 40ml of the 
continuous phase under mild stirring (400rpm) and allowed to stir overnight until the 
solvent evaporated.  
For the nanoprecipitation method[315], PLGA was dissolved in acetone in 
concentrations ranging from 10-40mg/ml. This solution was then added drop-wise using 
a 23G syringe into an aqueous surfactant solution under magnetic stirring at 400rpms. 
The PVA concentrations ranged from 1-10wt%. This mixture was left to stir at room 
temperature overnight until the solvent had evaporated.  
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For both procedures, the nanoparticles were then repeatedly centrifuged at 
15krpm and resuspended in DI water until negligible surfactant remained. Particle size 
and polydispersity were determined by photon correlation spectroscopy by using a 
Malvern Zetasizer (Malvern Instruments Ltd., UK). Nanoparticle batches were diluted in 
deionized water and measured in triplicate. 
6.2.3 Iodination 
Biotinylated diferric human Transferrin was labeled with 125I or 131I using the 
Iodogen technique[316]. First, solution of Iodogen in chloroform were prepared and 
added to reaction vessels so that they contained approximately 50µg of Iodogen. The 
chloroform was then evaporated under vacuum to leave behind a coating of the catalyst. 
Next, the reactant solution of approximately 15mg Tf-biotin, equal molar inert sodium 
iodide, and 1mCi of the radioisotope of choice in 5ml of HBSS buffer. This was then 
added to the reaction vessel and allowed to react for 45min. The components were then 
purified using PD-10 gel-filtration columns and eluted with HBSS. Reaction yield and 
extent of purification was determined using high-performance liquid chromatography 
(HPLC) with a radiometric detector, fitted with a size-exclusion column (7.5x675 mm 
TSK 3000SW, TosoHaas, Woburn, MA) eluted with 0.2M phosphate, pH 7.2 in 0.05% 
NaN3. 
6.2.4 Nanoparticle Conjugation 
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Figure 6-1: Nanoparticle surface coupling scheme 
 
 
 
Diamine polyethylene glycol (H2N-PEG-NH2) with a molecular weight of 
3400g/mol was purchased from Sigma. H2N-PEG-biotin was prepared by reacting 
diamine PEG with the NHS-biotin reagent[120]. Approximately 200mg of diamine PEG 
was dissolved in 2ml of phosphate buffer (0.1M sodium phosphate, 0.15M NaCl, pH 
7.2). A stock solution containing 20mg/ml NHS-biotin in dimethyl sulfoxide was added 
so that 12-fold molar excess to PEG was present. This was allowed to react at room 
temperature for 1hr and then purified over PD-10 columns eluted with DI water. The 
components were then freeze-dried for later use. The HABA-assay[274] was used to 
determine biotin content, which was around 1mol biotin/mol PEG. 
Nanoparticle-PEG-biotin conjugates were created using a modified version of a 
two-step EDC coupling method[120]. First, 100mg of prepared nanoparticles were 
washed and suspending in a coupling buffer (50mM MES, pH 6.0). 100mg of EDC and 
100mg of sulfo-NHS were then added to the buffer. Control samples contained an 
additional 100mM Tris, an amine containing buffer component. The particles were 
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allowed to react for 15min at room temperature, after which they were twice washed by 
centrifuging and resuspending them in coupling buffer. After the final wash step, the 
particles were resuspended in 5ml coupling buffer. Prepared H2N-PEG-biotin was then 
added in 10-fold molar excess to the nanoparticles, calculated using the number of 
theoretical carboxylic acid groups on PLGA. The components were allowed to react for 
4hrs at room temperature at mild magnetic stirring. Afterwards, the particles were 
washed like before with a 100mM Tris buffer to quench remaining binding sites. The 
nanoparticle conjugates were then washed in DI water and freeze-dried for later use. 
Post-conjugation size was determined using dynamic light scattering.  
Binding sites were determined using reagents from an avidin/biotin ELISA 
kit[275]. Briefly, 10mg of nanoparticles conjugates were suspending in 200µl of a diluted 
streptavidin-conjugated peroxidase (1:5000, 1mg/ml in PBS) and incubated at 37°C for 
1hr. The nanoparticles were then centrifuged at 15,000g and resuspending in PBS five 
times to wash the unbound streptavidin conjugate. The nanoparticles were then 
resuspended in 200µl of a peroxidase substrate solution (0.4mg/ml O-phenyl-diamine-
HCl, 0.02% v/v H2O2, 50mM Na2HPO4, 30mM citrate, pH 5) and incubated at 37°C for 
1hr. 
Nanoparticle-PEG-biotin conjugates were coupled with radiolabeled Tf-biotin 
using avidin in a two-step process. First, 200mg of prepared NP-biotin were 
resuspended in 5ml of HBSS. Then, 200µl of a 1mg/ml stock solution of avidin in HBSS 
was added and the mixture allowed to couple for 30min. The NP-biotin were then 
132 
 
centrifuged and washed multiple times with HBSS to wash uncoupled avidin before 
being resuspended in 5ml of HBSS. 1ml of radiolabeled Tf-biotin was then added to the 
mixture and allowed to couple for 30min. Excess Tf-biotin was then washed by again 
centrifuging the nanoparticles and resuspending in HBSS multiple times. At each step, 
the pellet was measured for radioactivity using a Spectech ST360 radiation counter (Oak 
Ridge, Tennessee, USA). 
6.2.6 Cell culture 
All cellular experiments were performed using Caco-2 cells obtained from Sigma 
Aldrich with passage number ranging from 45-55. Cells were grown until reaching 80% 
confluency, after which they were collected for the binding studies or seeded for the 
transport studies. For the transport studies, 12-well Corning (Tewksbury, 
Massachusetts) Transwell plates with 3µm pores were seeded with approximately 
50,000 cells. Cells were fed every other or third day. Tight junction development was 
monitored by measuring the trans-epithelial electrical resistance (TEER) with an 
epithelial voltohmmeter (EVOM2, World Precision Instruments, West Haven, CT). TEER 
values typically plateaued after three weeks, around 800 Ω·cm2, indicating fully 
developed tight junctions. 
6.2.7 Transport Studies 
Prior to the start of transport studies, culture media were removed from the 
Transwell trays and the wells washed three times with Hanks Buffered Saline Solution 
(HBSS). The cells were then incubated with HBSS for 1hr to deplete intracellular Tf 
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levels leftover from the serum, after which the buffer was then removed. Fresh HBSS 
was added to the basolateral chamber of the wells, while apical chambers received 
nanoparticle conjugates suspended in HBSS at a total concentration of 5mg/ml. Control 
wells included unlabeled, unconjugated Tf at a concentration of 1mg/ml. Samples were 
then taken at 30min, 60min, 90min, 120min, 180min, and 240min time points, with fresh 
HBSS added to replenish the sampled amount. The studies were conducted at 37°C. 
6.2.8 Scanning Electron Microscope Imaging 
Nanoparticles were visualized and sized using SEM. Samples were prepared by 
finely spreading concentrated nanoparticle dispersions over carbon tape and by drying 
them at ambient conditions. The samples were then coated with Pt/Pd in a Cressington 
sputter coater for 30 seconds at 40mA to create a 7-9 nm platinum layer and observed by 
SEM using a Zeiss Supra 50 VP scanning electron microscope. Image analysis was 
performed with the aid of ImageJ software (National Institutes of Health, Bethesda, 
Maryland, USA)[317] according the ISO 13322-1[318]. 
6.2.9 Statistical Analysis 
The results of each study are reported and plotted as the mean ± one standard 
deviation. Statistical differences were determined using ANOVA followed by post-hoc 
comparison testing to determine differences between individual means. Baseline level of 
significance was chosen to be α≤0.05, and more specific p-values are listed, where 
appropriate. Graphically, levels of significance are noted according to the following 
notation: * - p-value≤0.05; ** - p-value≤0.01; *** - p-value≤0.001. 
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6.3. Results 
6.3.1 Creating Nanoparticle-Transferrin Conjugates  
6.3.1.1 Nanoparticle Fabrication 
The goal of this study was to implement design of experiments (DOE) 
methodology to determine the controlling variables that affected size and size 
distribution for multiple nanoparticle fabrication techniques. The summarized results 
and trends are listed in table 6-1. We would then use these variables to create samples to 
test the hypotheses set forth in chapter 3. 
Particles obtained through the nanoprecipitation method had an adjustable size 
range from 207-309nm. Of the three methods, nanoprecipitation produced the smallest 
and most monodisperse samples. Though the polymer and surfactant concentration 
were determined to be the significant variables, they were found to only weakly 
correlate with size before their concentration reached a saturation point, which limits the 
range. The PdI did not correlate with any variables using this method.  
The particle morphology was more adjustable using the emulsion techniques, in 
which the mechanical properties of the process allowed for more variables. The 
sonicator was capable of producing particles ranging from 216nm to 402nm, with more 
monodisperse particles compared to the homogenizer, but more polydisperse than that 
of the nanoprecipitation method, with PdIs ranging from 0.028-0.171. Though size 
correlated with both PVA and PEG concentration, this was found not to be a linear 
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trend. Though the sonicator unit was capable of producing a higher power output, this 
was found to hinder the emulsion process.  
The homogenizer generally produced larger and more polydisperse particles that 
the other methods, ranging from 348-602nm and PdIs ranging from  0.033-0.149. Using 
this method, average diameter was found to correlate with PVA and PEG concentration, 
in addition to the homogenizer speed (a function of the emulsifying power input). In 
contrast to the sonicator, where larger particles were produced with increasing PVA and 
PEG concentrations, the homogenizer had the opposite effect, producing smaller 
particles. Also in contrast to the sonicator was the homogenizers ability to produce large 
particles with monodisperse distributions (602.4nm with PdI=0.058).  
 
 
 
Table 6-1: Nanoparticle DOE Summary 
 Zavg Diameter (nm) PdI 
Method Min Max Trend p-value Min Max Trend p-value
Nanoprecipitaiton         
PLGA conc. 212.4 280.0 YES 0.010 0.030 0.070 NO 0.308 
PVA Conc. 207.1 309.1 YES 0.023 0.016 0.045 NO 0.725 
Sonication         
PVA Conc. 215.6 401.9 YES 0.021 0.028 0.039 NO 0.476 
PEG Conc. 285.6 401.5 YES 0.011 0.054 0.171 YES 0.011 
Homogenizer         
PVA Conc. 355.3 536.2 YES 0.013 0.053 0.141 YES 0.018 
PEG Conc. 347.8 602.4 YES 0.013 0.058 0.159 NO 0.556 
Speed (kRPMs) 385.5 536.2 YES 0.010 0.052 0.141 NO 0.074 
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Figure 6-2 provides a summary of size profiles obtained using the various 
methods from above, listed in order of increasing average diameter. The error bars 
represent the polydispersity of the samples as one standard deviation from the mean 
size, rendered from the PdI using the following equation under the assumption that the 
particles are distributed normally: 
Eq. 6-1:  ܲ݀ܫ = ఙమ௓ೌೡ೒మ 
 
 
 
Figure 6-2: Nanoparticle size profiles 
 
 
 
Of the available size profiles, six samples were chosen to be used in the transport 
experiments, and they are described in table 6-2. Five of these samples were chosen 
because they were relatively monodisperse and spread across the size range. For brevity, 
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they will be named after the 100nm interval their Zavg diameter is closest to. An 
additional sample was chosen for being polydisperse but having the same approximate 
size range as the 400nm sample.  
 
 
 
Table 6-2: Nanoparticle Samples Chosen for Transport Studies 
 Sample Name Method Zavg (nm) PdI 
Monodisperse 
Samples 
1 200nm Nanoprecipitation 212.4 0.023 
2 300nm Nanoprecipitation 309.1 0.018 
3 400nm Sonicator 401.5 0.035 
4 500nm Homogenizer 518.3 0.052 
5 600nm Homogenizer 602.4 0.058 
Polydisperse 6 High PdI Sonicator 401.9 0.171 
      
 
 
 
6.3.1.2 Transferrin Iodination 
After allowing the materials to react, samples were analyzed via high-
performance liquid chromatography to ensure the reaction had proceeded as desired. 
Using a size-exclusion column, the two components can be separated, Tf first, followed 
by the unreacted radiolabel, as seen in figure 6-3. By comparing the ratios of the area-
under-the-peak for the two components, the reaction yield can be determined. The 
reactions had an average reaction yield of 62.3%, and samples less than 50% were 
transferred to new reaction vials until the yield increased. When the yield was 
determined to be satisfactory, samples were purified and reanalyzed using HPLC. 
Samples routinely yielded a purity over 99%, confirming that little unreacted radiolabel 
remained with the purified sample. 
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Figure 6-3: Transferrin Iodination. 
 
 
 
6.3.1.3 Nanoparticle Conjugation 
Using the avidin-catalyst from the biotin ELISA, the available binding sites for 
the chosen particles samples were determined and are listed in table 6-3. Binding sites 
were found to vary with both size and production method used. In general, smaller 
particles, having a larger total surface area per unit of mass, had more binding sites. 
However, during the emulsions processes, the hydrophilic interactions along the phase 
interface causes the PLGA carboxylic acid end groups to orient themselves along the 
surface, often making up for the smaller surface area[319]. For this reason, particles 
obtained using the sonicator, with a Zavg diameter of 400nm, had comparable binding 
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sites with particles obtained through the nanoprecipitation method (231±28 vs. 225±11 
nmol/100mg), even though their surface areas considerably less than the 200nm 
particles.  
 
 
 
Table 6-3: Surface Binding Sites of Nanoparticles/100mg Particle 
 Sample Method Surface Sites (nmol) 
Monodisperse 
Samples 
200nm Nanoprecipitati
on 
231 ± 28 
300nm Nanoprecipitati
on 
185 ± 22 
400nm Sonicator 225 ± 11 
500nm Homogenizer 122 ± 15 
600nm Homogenizer 110 ± 11 
Polydisperse High PdI Sonicator + PVA 201 ± 14 
      
 
 
 
 
To bind the radiolabeled Tf-biotin to the nanoparticles, the nanoparticles were 
first saturated with excess avidin. Avidin was added in 100x molar excess of the biotin 
sites to restrict nanoparticle-nanoparticle binding. After washing, the particles were 
combined with the radiolabeled Tf-biotin to allow the second avidin-biotin coupling 
step to occur. All samples received 125I with the exception of Sample 5, which received 
131I for the purpose of the competition transport study. The subsequent wash steps were 
monitored using a bench top Geiger counter to both track the purification and to 
determine the extent of binding, and are plotted in figure 6-4. The results of the wash 
steps indicate that supernatant radioactivity levels were below the detection threshold 
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after the third wash step. Two additional wash steps were performed to further 
eliminate free labeled-Tf. 
 
 
 
Figure 6-4: Supernatant Radioactivity During Nanoparticle Wash Steps 
 
 
 
6.3.2 Transport of Monodisperse Nanoparticles 
6.3.2.1 Mass Analysis 
The transport results for the monodisperse nanoparticle samples in terms of 
mass are presented in figure 6-5. The amount of radioactivity determined in the 
basolateral samples was converted to mass using standards derived from the known 
mass and radioactivity of nanoparticles dosed in the apical chamber. Control samples 
resulted in transport of less than 1ng for all time points (not shown), which was 
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subtracted from the non-control studies to give the result of specific RME-transport. 
Transport accumulation increased at each time, reaching a maximum at the 4hr time 
point. This maximum is presented in figure 6-6. The 300nm sample resulted in the 
highest accumulated mass of nanoparticles, reaching 216±22ng, followed by the 400nm 
sample, which accumulated 149±20ng. Both of these samples were significantly higher 
than each other and the remaining samples (p<0.001). The 200nm, 500nm, and 600nm 
samples were not significantly different from each other. 
 
 
 
Figure 6-5: Tf-Nanoparticle Transport vs. Time by Mass 
 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
0 50 100 150 200 250 300
N
an
op
ar
tic
le
 T
ra
ns
po
rt
 (µ
g)
M
AS
S
Time (min)
200nm
300nm
400nm
500nm
600nm
n = 6
142 
 
 
Figure 6-6: Cumulative Transport of Nanoparticles by Mass 
 
 
 
6.3.2.2 Transport of Monodisperse Nanoparticles by Number 
To convert the mass of nanoparticles to particle count, nanoparticles were made 
using three methods used in table 6-3 (Nanoprecipitation, Sonicator, and Homogenizer) 
and prepared for analysis by the Nanosight Applications Laboratory. The analysis 
returned the particle concentration, from which the particle density could be obtained 
using the following equation [5]: 
Eq. 6-2: ߩ = ଺∙௠గ∙௡∙௓ೌೡ೒య 
where m is the mass of particles in solution, n is the particle count, and Zavg the 
particle diameter. It was assumed particles made using the same method have the same 
nanoparticle density. Using the derived density and the same equation, we could go 
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back and determine the particle molar mass for each tested sample. The results of these 
conversions are listed in table 6-4. 
 
 
 
Table 6-4: Particle Concentration Analysis 
Sample Method 
Particle Molar Mass 
(fmol/ng) 
200nm Nanoprecipitation 3.0 
300nm Nanoprecipitation 10.2 
400nm Sonicator 18.1 
500nm Homogenizer 39.1 
600nm Homogenizer 67.6 
 
 
 
The accumulated mass of the nanoparticle observed during the transport studies 
was converted to a particle count using the conversion factors determined in the 
previous section. The accumulations of nanoparticles with respect to time are plotted in 
figure 6-7, while the maximum values, determined at the 4hr time point, is plotted in 
figure 6-8. 
Similar to the Transport by Mass profile, accumulation of nanoparticles in the 
basolateral chamber began after 30min and continued to increase until the end of the 
experiment. However, due to the differing molar mass of the different sized particles, 
the order changed: the 200nm particles accumulated in the highest number, reaching 
264±17fmol, followed by the 300nm samples, with 211±21fmol. The other particles 
followed in decreasing order according to diameter. The 200nm, 300nm, and 400nm 
samples were statistically different from all samples, while the 500nm and 600nm 
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samples, though significantly less that the smaller particles, were insignificantly 
different from each other (p<0.001). 
 
 
 
Figure 6-7: Nanoparticle Transport Accumulation vs. Time by Number 
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Figure 6-8: Cumulative Transport of Tf-Nanoparticles by Number 
 
 
 
 
6.3.3 Transport of Polydisperse Nanoparticles 
6.3.3.1 Comparing Polydisperse and Monodisperse Particles 
The transport of a polydisperse sample with a Zavg of 400nm was tested and 
compared against the previous 400nm sample. The total accumulations at the 4h time 
point are plotted in figure 6-10. While the previous 400nm sample had 1.49±0.20µg 
transported, the 400nm-High PdI sample had significantly less transported, 
accumulating only 0.71±0.05µg (p<0.001). 
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Figure 6-9: Comparing Transport of Monodisperse and Polydisperse Samples
 
 
 
6.3.3.2 Competitive Bimodal Transport Study 
Two monodisperse samples used in previous transport studies, the 200nm and 
600nm samples, were mixed in varying ratios to achieve bimodal mixtures with different 
Zavg diameters than the separate samples alone. The resulting Zavg diameters, as 
determined by dynamic light scattering, are plotted in figure 6-10 as a function of the 
small (200nm) to large (600nm) nanoparticle mass ratio. The inclusion of the large 
particles has an effect even at ratios as high as 100:1, producing an average diameter 
60nm higher than the 200nm sample alone. A mass ratio of 8:1 was found to produce a 
Zavg diameter of 407nm, with a PdI of 0.176, comparable in average size to the 400nm 
sample, but with a wider distribution. The Zetasizer was unable to distinguish the 
separate, bimodal peaks. 
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Figure 6-10: Average Diameter of Bimodal Nanoparticle Systems by Dynamic 
Light Scattering 
 
 
 
Having determined the necessary ratio, a bimodal sample was created using the 
previously radiolabeled samples, the 200nm sample with 125I-Tf and the 600nm sample 
with 131I-Tf, so that they could be distinguished from one another. A transport study was 
then conducted with the bimodal mixture, along with control samples with excess free 
Tf, to determine the extent of RME transport for the competing particles. The maximum 
transport achieved for the two samples at the 4hr time point is plotted in figure 6-11. 
Here, the 200nm sample was found to have transported 0.675±0.018µg, while the 600nm 
only had 0.045±0.003µg transported, a 15-fold difference (p<0.001). 
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Figure 6-11: Competitive Transport of Bimodal Nanoparticle Samples 
 
 
 
6.3.4 Imaging Nanoparticle Transport 
New Nanoparticles samples were created and conjugated with non-radiolabeled 
Tf, using the same methods described previously. The DLS analyses of these samples are 
listed in table 6-5. Transport studies with these particles were conducted, and the 
basolateral samples collected for image analysis and compared with images of the 
original samples from the apical wells. 
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Table 6-5: Nanoparticle Samples Chosen for 
Transport Studies 
Sample Name Zavg (nm) PdI 
1 Polydisperse 420.2 0.142 
2 Monodisperse 276.3 0.016 
 
 
 
The polydisperse sample contains a wide distribution of particles (figure 6-12). 
Larger particles above 650nm in diameter are present, though the freeze-drying process 
appears to collapse these particles. More numerous are particles in the 200-400nm range. 
The histogram produces a number-average particle size of 353±172nm. Basolateral 
samples, however, produce a smaller and more narrow distribution in comparison, with 
most particles concentrated between 100-300nm, with no particles observed above 
500nm (figure 6-13). The number-average particle diameter was determined to be 
165±46nm. 
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Figure 6-12: SEM Image of Original Polydisperse Sample and Size 
Distribution 
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Figure 6-13: SEM Image of Transported Polydisperse Sample and Size 
Distribution 
 
 
 
 
The monodisperse sample was more uniform in comparison to the polydisperse 
sample, with most particles observed to between 100-250nm in diameter, though the 
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sample also contained particles above 500nm. The number average diameter was 
determined to be 209±75nm. The transported sample was also found to be smaller and 
more monodisperse than the original sample, with a number average diameter 
determined to be 174±48. 
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Figure 6-14: SEM Image of Apical Monodisperse Sample and Size 
Distribution 
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Figure 6-15: SEM Image of Transported Monodisperse Sample and Size 
Distribution 
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6.4. Discussion 
6.4.1 Creating Nanoparticle Conjugates 
The goals of these experiments were to develop the necessary techniques to 
fabricate the nanoparticles required to test the hypotheses outlined in chapter 3. The 
choices of materials were made based on a number of reasons: (1) biotin, avidin, PLGA, 
and PEG are all biocompatible and non-toxic compounds and have been used in prior 
FDA-approved drug products[320], (2) the biotin-avidin ELISA substrates can be used to 
determine extent of nanoparticle labeling, and (3) safety concerns regarding the use of 
radiolabeled compounds. 
The size range obtainable using the three methods used ranged from 200-600nm. 
Attempts to produce larger particles resulted in samples much larger than 1µm and 
were not suitable for cell work. Smaller particles, though achievable using the methods 
described in this work, required more powerful equipment to emulsify and separate 
than what was available. 
The nanoprecipitation method produced the most uniform and monodisperse 
particles. This is in part due to the mechanism which causes particles to form: when a 
polymer/solvent mixture is added to an aqueous solution, the mixture undergoes rapid 
desolvation, precipitating the polymer into a hardened sphere[321]. The rate of 
precipitation is governed by a variety of chemical properties, such as surface tension and 
diffusion, and are mostly independent of user input[322]. This makes for a more 
accurate and reliable process at the expense of customization: the two variables found to 
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alter the  nanoparticle size, the polymer and surfactant concentration, only produced a 
size range 200-300nm. 
The emulsification method, on the other hand, requires an externally applied 
energy force to form particles. This allows for a greater degree of tunability, increased 
further by the advantages officered by using two emulsifying units, a sonicator and 
homogenizer. The sonicator, while generally producing monodisperse particles at lower 
size ranges (200-400nm), was found to be susceptible to forming polydisperse particles 
when used in highly viscous solutions, which had been observed previously and 
attributed to the impedance of cavitation[323]. The homogenizer, however, was more 
adept at handling more viscous solutions, and provided the necessary particles samples 
at the higher size ranges (350-600nm), while still maintaining monodispersity. 
After these desired samples were selected, the first surface conjugation step 
proceeded with the covalent attachment of H2N-PEG-biotin. An analysis of this reaction 
reveals the number of binding sites per mass of nanoparticle differs for each sample. 
This is due to several factors: the orientations of the carboxylic acid groups align 
themselves differently with the different fabrication methods; the relative surface area of 
the nanoparticles decreases with increasing diameter; and the densities of the particles 
produced by different methods, as determined later with the Nanosight® analysis, are 
different. This introduces relative binding sites are a potential variable in RME-
transport, though this was not further explored. 
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Determining the nanoparticle binding sites also served as a proof-of-concept for 
the next binding stage, which involved the addition of an avidin bridge and the 
radiolabeled Tf-biotin molecule. The avidin/biotin ELISA assay reagents used for 
quantifying the sites utilize an avidin-catalyst bridge, merely a conjugate avidin 
molecule, for colorizing the substrate solution. The success of this analysis step proves 
that binding occurs. In addition, the lack of colorization in the control studies proves 
that both the PEGylation reaction occurred and that avidin does not bind non-
specifically to the nanoparticle surface in significant amounts.  
Transferrin iodination proved successful, with little free radiolabel remaining 
after purification. This is important, as the high sensitivity of the label would be a source 
for background noise in future studies. The high sensitivity of the label also requires that 
an extremely small proportion of the total Tf be labeled (<0.5%). Iodine, a large, 
electronegative ion, has the possibility of altering both the physical and biological 
properties of Tf, as it has shown with other ligands, like calcitonin[324]. Based on this, 
inert iodine was added to the reaction in stoichiometric proportions to Tf so that every 
atom would be tagged with an iodine atom. 
6.4.2 Transport of Monodisperse Nanoparticles 
Control samples with excess unlabeled Tf resulted in transport significantly 
lower that the non-control studies in all cases. If the detected radiolabel were to be 
assumed to be completely associated with nanoparticles, this would correlate with less 
than 1ng of nanoparticles transported, though at these low levels, the possibility exists 
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that free radiolabeled Tf remains left over from the purification stage, and the control 
samples are the results of the non-specific transport of both nanoparticles and free 
ligand. This reiterates the successful development of the monolayer tight junctions and 
their ability to act as a barrier for passive transport. 
Ligand studies from chapter 5 resulted in passive transport levels as high as 
255fmol for the high-dose study, approximately 20ng of Tf, well above the levels found 
in these studies. The size of the nanoparticles, two orders of magnitude above that of the 
free ligand, hinders their diffusion across the cells, resulting in poor transport and 
ineffective drug-carrying vehicles on their own. Nanoparticles utilizing RME, on the 
other hand, resulted in a considerable increase in transport across the monolayers: 
basolateral transport ranged from 0.80±0.05µg with the 200nm sample, and reached as 
high as 2.16±0.22µg with the 300nm sample. This is a 90-fold increase from the highest 
RME-levels observed of the ligand alone in chapter 5 (308fmol, 24ng). This successfully 
demonstrates the payload capabilities of the RME pathway. 
Unlike the trend observed in the ligand-only transport studies, basolateral levels 
of nanoparticle-Tf accumulated gradually rather than sharply and without the plateau 
effect. The number analysis of these accumulations (figure 6-7) showed none of the 
samples reached their maximum transport levels (~300fmol), as determined from the 
receptor and transport studies in chapter 5. The 200nm sample come closest to 
approaching this level, reaching a maximum of 264±17fmol at the 4hr mark, though due 
to time constraints the studies had to end at this point. The trend is not linear, however, 
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and appears to level off toward this maximum threshold. As the size of the nanoparticles 
increases, accumulation decreases, indicating that the rate of uptake is affected 
negatively by the size of the particle. This corroborates the conclusions of previous 
studies suggesting that uptake is size dependant, though to a greater degree than simply 
a threshold. The effect of this size-dependency resulted in 95% fewer transported 600nm 
particles than 200nm particles. 
The decline in the number of nanoparticles transported does not directly 
correlate with particle mass transport, however, due to the different relative payload 
levels of the different sized particles. From the particle concentration analysis (table 6-4), 
we found that the particle molar mass increases with increasing diameter. The weight of 
this relationship is dependent on the volume of the particle and the density, though 
volume carries much more influence here since volume is a function of the particle 
diameter to the third power. This is what makes a 600nm particle carry 27-times the 
mass of a 200nm particle. 
These two trends, the decline in the total number of particle transport and the 
increasing payload of particles as diameter increases, combine to produce the results of 
the particle mass accumulation (figure 6-5 and figure 6-6). Here, the 600nm particle 
samples had comparable transported mass to the 200nm samples, despite the significant 
drop in the number of particles transported, due to their increased payload. The 300nm 
particles, which had only 20% fewer particles transported than the 200nm samples, 
carried 160% more mass across the monolayers, making them the most effective drug 
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carrier of the samples tested over the 4hr period. Above 300nm diameters, the drop in 
the number of particles transported offset the increased payload.  
Had the transport studies continued beyond the 4hr mark, it is worth 
considering the potential results of the studies: while the 200nm and 300nm particles 
will have leveled off after little more than an additional two hours, the remaining 
particles samples would continue to accumulate samples until their receptors were 
exhausted. This would contribute significantly more to their total payload, thus making 
them more successful in comparison. However, this would not represent a realistic 
scenario in vivo, as the nanoparticles would be cleared from the body. 
6.4.3 Transport of Polydisperse Nanoparticles 
To test the influence of a sample's polydispersity on monolayer transport, we 
compared two samples with similar average diameters, approximately 400nm, with 
differing size distributions. The monodisperse sample, test in the previous section, 
accumulated 1.49±0.20µg in the basolateral compartment. The cells receiving the 
polydisperse sample, on the other hand, transported less than 50% of that amount 
(0.71±0.05µg), demonstrating the negative effects of a polydisperse sample. No number 
analysis was conducted on the polydisperse sample, as any conversion from a mass to a 
number count would require that all particles are uniform.  
The difference between the two samples lies in the increased proportions of 
particles both larger and smaller than the average size. It was hypothesized that the 
smaller particles present scavenge the limited receptors available for particle transport at 
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the expense of more mass-heavy ones, thus decreasing the overall amount of 
transported mass. To test this hypothesis, polydisperse sample were created comprised 
of two samples tested previously, the 200nm and 600nm samples. The mixed sample 
found to most closely resemble the previous polydisperse sample in Zavg diameter 
required a mass ratio of 200nm to 600nm particles of 8:1, heavily favoring the 200nm 
sample in both mass and number (figure 6-10). The raw distribution determined from 
dynamic light scattering units is derived from intensity of scattered light, which 
proportional to the sixth power of a particle's diameter[222]. Because of this, bimodal 
mixtures tend to produce Zavg diameters that closely match the larger of the two peaks, 
but with a larger polydispersity [325, 326]. In this case, despite the 200nm particles 
heavily outnumbering the 600nm particles, the mixed sample retained many of the 
characteristics of the larger particles, resulting in a polydisperse sample with an average 
diameter between the two samples. It should also be noted that the CONTIN analysis of 
these mixtures, usually the preferred method when dealing with bimodal samples, 
failed to identify the separate peaks of the two samples. It has been shown previously 
that DLS can only resolve two populations with a diameter ratio greater than 2.71[327], 
and though these two samples exceed that ratio (3 vs. 2.71), the ratio may not be large 
enough in this case. In addition, it has been found that the ability of DLS to resolve two 
size distributions is not only limited by size ratio but the number ratio of two 
populations[328]. 
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Once the proper ratio had been determined, the 600nm particles were given a 
131I tag to distinguish them from the 125I tags applied to the 200nm particles. The 
results of the transport study leaned heavily towards the 200nm particles, whose 
basolateral mass accumulation was 14-fold that of the 600nm sample (figure 6-11). The 
mass accumulation of the 600nm particles was significantly less than compared to the 
studies with 600nm particles by themselves. The accumulation of 200nm particles, on the 
other hand, was not significantly different when mixed with the 600nm particles than 
without. This is due to the small number of larger particles in comparison, which do not 
significantly impede the transport of the 200nm particles. 
SEM imaging of provided a convenient method for visualizing this effect as well. 
In one study, a polydisperse sample originally had a number average of 353±172nm, 
with particles ranging from 100-900nm (figure 6-12). However, when transported 
through the RME-pathway, only particles ranging from 100-300nm were observed, with 
an average particle size of 165±46nm. Even the monodisperse samples, which had an 
originally tighter distribution, experienced a shift towards a smaller average once 
transported (209±75nm vs. 174±48nm, figure 6-15). The latter example demonstrates how 
even samples considered monodisperse have imperfect distributions that make them 
susceptible to this downward shift in size once transported. 
6.5 Conclusions 
The number-analysis results confirmed previous conclusions that the RME-
pathway is a size-dependant process: Smaller particles were found to accumulate faster 
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and in greater number than larger particles over the four-hour process. Rather than 
excluding particles above a certain size threshold, however, the cells successfully 
managed to transport all particles in the size ranges tested, 200-600nm, and found the 
rate of transport to slow down with increasing size. While this suggests that, had the 
studies continued beyond the allotted time, the larger particles would have caught up to 
the smaller particles, such time lengths would be impractical in in vivo situations. 
These results suggest that, by themselves, smaller nanoparticles are superior 
drug delivery devices because they are transported in greater number. However, as 
discovered in the previous chapter, overall transport is limited by the number of ligand 
or ligand-particle devices being carried across, as a result of the cellular receptor cycle. 
The smallest sample tested, with an average diameter of 200nm, approached 90% of this 
maximum value, leaving little room for improvement. This eliminates the possibility of 
simply administering a larger dose in order to achieve higher drug transport. 
This limit provides an advantage to larger particles: when limited to a finite 
number, larger particles will deliver higher therapeutic doses across monolayers 
compared to their smaller counterparts. Thus, when there was only a 20% difference in 
the amount of transported particles between the 200nm and 300nm particles, the 300nm 
particles samples carried a significantly higher amount of mass. Above 300nm, the drop 
in number particle transported counteracted their larger mass, resulting in a net 
decrease in mass transported. Even with a 95% drop in the total number of particles 
delivered, the 600nm samples carried just as much mass as the 200nm samples. These 
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results demonstrate that, for a given particle-ligand combination, there likely exists an 
optimal size range where the competing advantages of higher particle transport against 
larger payloads combine to produce an optimal size. 
In a polydisperse sample, it was shown that both small and large particles 
compete against each other for the limited receptor sites. This comes at the cost: small 
particles that are greater in number were transported in higher amounts and prevented 
larger particles from binding with the receptors. In the bimodal sample tested, the result 
of the transport study most closely matched the smaller and more populous of the two 
mixed samples, and was significantly different from the monodisperse sample with 
matching average size. This demonstrates that polydisperse samples behave differently 
than their average size suggest. How this size is determined and subsequently reported 
has the potential to produce misleading results: Zavg sizes, as determined using dynamic 
light scattering, are heavily influenced by larger particles, making a sample appear 
bigger than its population would suggest; Number-based averages, such as those 
determined from imaging analysis, neglect the larger-massed particles which would 
hold a proportionally higher drug load. The wider the size distribution, the greater the 
difference between these analyses, and the results they produce. Monodisperse samples, 
on the other hand, are accurately represented using all average types. 
These results demonstrate how it is possible to predict two key factors for 
nanoparticle-based RME-drug delivery: First, nanoparticle samples which achieved the 
highest transported mass can be used to predict the realistic RME-transport dose when 
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combined with typical drug loads. This value incorporates the physical limitation of the 
cell and variables of the nanoparticle, such as surface ligand density and surface charge. 
Second, the receptor limit, nanoparticle masses, and drug loading can be combined to 
predict the maximum achievable RME-transport dose; The latter value would be the 
result if all variables of the nanoparticle were optimized and the slowed transport time 
were of no consequence. By comparing the required dose for a given therapeutic and the 
maximum achievable RME-transport, it can be determined if nanoparticulate drug 
delivery devices should be pursued. Once this has been determined, the difference 
between the realistic and maximum achievable RME-transport doses can be used to 
compare to determine if optimization is necessary.   
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Chapter 7: Conclusions and Future Recommendations 
7.1 Conclusions 
Drug transport across the GI tract and blood-brain barrier (BBB) remains a 
significant obstacle, particularly for high molecular weight and hydrophilic therapeutics. 
A considerable amount of research has been devoted to exploiting receptor-mediated 
endocytosis (RME) pathways, themselves tasked with transporting large molecules, to 
improve the uptake poorly permeable drugs. Rather than characterizing these novel 
therapeutic formulations with respect to the performance of the drugs they were 
modifying, as most studies do, this work focused on searching for an alternative 
benchmark that would more appropriately assess their achievements. In short, we 
proposed asking the question: "What are the therapeutic transport capabilities of the 
RME pathway?" 
To answer this, our goal was to first develop pharmacokinetic model that took 
into account relative steps of endocytosis; such models have previously proven to be 
effective at predicting drug absorption, distribution, metabolism, and clearance of 
therapeutics. A generalized RME-model developed by Krippendorf et al. was adapted 
for a representative ligand, transferrin (Tf), in monolayer geometries[1]. Values for rate 
constants of each endosomal step were taken from kinetic studies on Tf in human 
hamtoma cells by Ciechanover et al.[2]. Receptor-density studies indicated that Caco-2 
cells, a human colon carcinoma line used for studying GI tract transport, had a binding 
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site density of 1.08x106/cell, which results in an estimated 320fmol of apical binding sites 
per in vitro Transwell® insert. 
Simulations of transport studies demonstrated how apical binding sites saturate 
readily when ligand concentrations are in excess. Internalized endosome levels briefly 
spike before decreasing as the ligand-receptor complexes are transported to the 
basolateral side. This resulted in a depletion of apical receptors in stoichiometric 
proportion to transported Tf levels, which ceased to increase once there were no more 
receptors to bind with the ligand. This established the correlation between available 
receptor pools and cellular transport capabilities, which results in an upper transport 
limit. Experimental studies corroborated these results, coming to within 8% of the model 
predictions (298±22fmol). Of note was a 30min lag between experimental and simulation 
values, which is likely due to the presence of additional endosomal steps (i.e. sorting, 
recycling endosomes) in polarized cells not accounted for in the kinetic model 
developed by Ciechanover. This lag was accounted for in subsequent simulations. 
Currently used assessment methods were found to be inadequate in describing 
the transport of RME-based therapeutics, due to their reliance on normalizing the 
transport with respect to the applied dose. This practice is based on the assumption that 
these drug formulations are transcytosed by passive-mechanisms that are driven by 
concentration gradients, such as diffusion. In studies varying the apical ligand 
concentrations, this assumption was valid for the control studies, which demonstrated 
that non-specific transport of Tf was proportional to the starting dose. No changes in 
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RME-transport were observed, however, as the 10, 1, and 50µg/ml studies reached the 
transport limit (298±22, 293±20, and 308±34fmol, respectively).  
Changes in RME-transport were observed, however, in studies evaluating 
different dose regimes. In studies attempting to mimic short-term, back-to-back dosings, 
cells were found to remain polarized after initial ligand transport and insufficient 
equilibrium times, resulting in diminished RME-transport (126±25fmol). Studies 
evaluating the effects of long-term use of ligand-therapeutics also observed diminished 
transport (247±38fmol). Receptor-density studies confirmed that this was due to 
diminished receptor levels (8.82x105 binding sites/cell), resulting in receptor down-
regulation. In both cases, non-specific transport remained unchanged. 
When evaluating only total transport, RME-based therapeutics appear superior 
to control values in all cases. While this is desirable, this can mislead researchers to the 
conclusion that these therapeutics could be optimized to further enhance transport. 
However, in all studies conducted, RME-transport reached their transport limit, 
indicating transport cannot be improved. These points demonstrate the impact of 
imparting therapeutics normally transported through passive mechanisms with 
saturable, pharmacokinetic profiles: this does not improve the non-specific uptake of the 
drug directly - it adds a second, independent transport pathway governed by different 
parameters. Conclusions based on these results should take into account the 
performance of the RME-pathways, not just the therapeutic. 
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Limitation of ligand uptake capacity across the GI tract have previously been 
noted for the vitamin-B12 ligand, which we now believe is due to the finite amount of 
available receptors[3]. To overcome this, nanoparticles have been suggested due to their 
ability to carry larger payloads. In this research project, we investigated the potential for 
nanoparticles of different sizes to amplify the endosomal transport capacity in light of 
their documented hindrance to uptake rates. When analyzing transport with respect to 
the total numbers of nanoparticles, we found that larger particles placed a significant 
burden on the cell's ability to transport them: particles 600nm in diameter only reached 
4% of the predicted transport limit by the end of the studies; in contrast, 200nm particles 
reached 88% of the limit, a 24-fold difference. However, due to the higher payload 
capacities of larger particles, the 600nm and 200nm samples actually transport similar 
amounts of total mass (0.79 µg vs. 0.80µg). The 300nm sample, having the right 
combination of mass payload while not having a large size burden, was found to be the 
optimal size, carrying 2.1µg across the monolayer. 
Polydispersity was also found to have a significant impact on transport. When 
comparing two samples having the same approximate average diameter (400nm) while 
having different size distribution, the sample with the higher PdI transported less than 
50% of the monodisperse sample. In a follow-up study, transport of bimodal samples 
containing a mixture of two monodisperse samples (200nm and 600nm) resulted in a 
heavy bias towards the smaller samples (15-fold difference in mass transport), due to 
their large number population. This demonstrated how polydisperse samples carry the 
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disadvantages of both small and large sample populations: a large number of small 
particles, carrying little mass, saturate the receptor-pathway, while larger particles 
carrying most of the mass are less readily transported. SEM imaging was able to 
visualize this "shift" in the size profiles, and proved that even the most monodisperse 
samples were not immune to this effect. This suggests that the results of our 
"monodisperse" transport studies underestimated that number of particles transported. 
In conclusion, this research demonstrates how ligands, when analyzed in the 
context of drug transport studies, can set benchmarks for the proper assessment of RME-
based drug delivery vehicles. Pharmacokinetic models of ligands, derived from 
literature and adapted for these purposes, can predict the upper transport potential of 
these therapeutics when combined with receptor-density studies. Together, they can be 
used to potentially screen for ligand-receptor pairings suitable for a particular 
therapeutic before in vitro or in vivo studies are pursued. If the transport limit is below 
the concentration required to obtain a therapeutic effect, nanoparticle delivery systems 
should be pursued. Blank nanoparticles, like those used in this body of work, can 
themselves be the benchmarks for drug transport, as it is easy to estimate the possible 
drug payload of nanoparticles given their transport potential. 
7.2 Future Recommendations 
Transferrin was chosen as a representative ligand because it one of most 
extensively studied transporters and has a long history in RME-based therapeutics, but 
there is no indication that this ligand is the most optimal. As transport potential was 
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linked to receptor availability, potential ligand-receptor pairings could be chosen based 
on receptor-density studies, which are well suited for high-throughput screening 
methods [4-6]. However, other properties beyond receptor count may factor in ligand 
choice, such as whether or not the receptor undergoes lysosomal degradation. 
Caco-2 cells are the de facto cell line for oral drug permeability studies and 
popular in BBB applications as well. This line is a cancerous line, however, and it is well 
documented that malignant cells over-express housekeeping receptors such as 
transferrin[7-9]. Therefore, these cells likely overestimate the transport potential of 
healthy GI tract cells. While these studies were designed only to demonstrate that 
transport limits exists due to receptor thresholds, these capacities should not be taken to 
be absolute, and the receptor-densities and cell kinetic should be assumed to be different 
for all cell lines. Future studies should consider alternative, non-malignant cell lines. 
In order to validate the use of the Caco-2 or other proposed cells lines for 
anticipating ligand uptake in humans, attempts must to be made to correlate in vitro and 
in vivo uptake. Typically, the permeability of these therapeutics is measured, often in the 
form of apparent permeability (Papp), and it is known that Papp values between 10-6 cm/s 
and 10-5 cm/s anticipate 100% in vivo absorption[10, 11]. However, in this work, we 
found Papp assessments not to be applicable to RME-transport mechanisms, and thus 
other models must be developed. Combining permeability and RME pharmacokinetic 
models (the latter being similar to the one proposed in this work) would accomplish 
this, though this would require knowledge of the RME-transport capabilities and 
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receptor thresholds in vivo. These could be determined with similar ligand-transport 
studies used in this research, accompanied with controls that flood the receptors, which 
demonstrated how the maximum transport plateau values corresponded to apical 
receptor levels.  
Despite the abundance of work examining the endocytosis, many details of this 
process are still unknown, primarily due to the difficulty in resolving endosome 
populations into their component parts. The model used in this work assumed equal 
rates for apical and basolateral sorting patterns, implying that only 50% first-pass 
basolateral transport is possible (this still allows apically recycled receptors to repeat the 
transport process). However, there is evidence to suggest that polarized cells have the 
capacity to direct endosomal compartments to basolateral sides, as opposed to this 
simply being a byproduct of random sorting patterns[12]. Exploiting basolaterally-
directed sorting patterns to achieve higher transport efficiency.  
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